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Introduction
The NHMRC Clinical Trials Centre at the University of Sydney runs large 
multicentre investigator-initiated clinical trials, undertakes research with 
national and international trial groups, and contributes expertise to trials 
run by others.  It also:
•	 takes a lead in proposing new directions for clinical research in Australia, 
particularly research aligned with national policy and clinical practice
•	 participates in translational research, from bench to bedside
•	 conducts methodological research in relation to clinical trials
•	 reviews and synthesises evidence from completed trials, and is at the 
forefront of developments in methods, such as prospective meta-analysis
•	 supervises postgraduate students in all of these areas
•	 offers postgraduate degrees in clinical trials research
•	 runs short courses to train people for Australian medical research.
The CTC also offers health technology and diagnostic test assessments, 
economic analyses, biostatistical design and analysis, and automated  
central randomisation services (IVR and IWR).
Core funding is provided by the NHMRC, and specific projects are funded  
by government, public and private institutions and the pharmaceutical 
industry. 
The CTC is at two sites in Camperdown in inner Sydney — the Medical 
Foundation Building on Parramatta Road and on Mallett Street.
This report covers the CTC’s achievements for 2012.  
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Directors’ report
2012 was a year of broad achievements, reflecting the 
continuing efforts of the CTC and its collaborative groups 
of investigators. Our activities, covering the spectrum 
of clinical research modalities from the laboratory to 
the clinic, will benefit a wide range of people: notably 
those with diabetes, cardiovascular disease and cancer, 
and newborn infants. We built capacity for future 
research and health care through education programs 
and PhD projects, several completed this year. We used 
systematic reviews and health economic studies to 
better inform practice and policy, and developed several 
improved methods for design and interpretation of 
trials. The common research themes of translation and 
interpretation in our program will be continued with the 
support of a new program grant to start in 2013.
Some of our achievements are the result of sustained 
research projects continuing over several years. An 
example is our ASPIRE study, whose results—a new use 
for an old drug—were published in the New England 
Journal of Medicine and presented at the American Heart 
Association meeting in November. We found that long-
term low-dose aspirin is an effective preventive treatment 
for patients with unprovoked venous thrombosis who 
are no longer on anticoagulation. A change in practice is 
likely to lead to significant health benefits and savings of 
health care costs internationally, far exceeding the cost of 
this trial.
New evidence is emerging on a question occupying 
neonatologists for a long time: the optimal target 
oxygen level for premature infants. The BOOST II 
study has provided some of this evidence and BOOST 
II data is contributing to the worldwide collaboration, 
NeOProM, aiming to definitively and finally establish the 
optimum oxygen saturation target for these infants. This 
collaboration, led by CTC, will prospectively combine the 
results of the five current international neonatal trials 
of oxygen therapy for premature newborns. Prospective 
meta-analysis of data from several trials can provide 
more reliable evidence of treatment effects for research 
questions about relatively uncommon conditions or 
where the effects of treatment are subtle, for which 
vast numbers of patients may be required. Similarly, in 
cardiovascular disease, our LIPID trial contributes to the 
huge database and meta-analyses of the international 
Cholesterol Treatment Trialists’ collaboration, co-
coordinated by the CTC and the Clinical Trial Service 
Unit in Oxford. Its latest analysis shows that women and 
people at very low risk of cardiovascular events can benefit 
from lipid-modifying treatment. 
Unbiased evidence for these and similar meta-analyses 
relies on the registration of all trials worldwide. The 
Australian New Zealand Clinical Trials Registry (since  
2005 a primary registry of the WHO international 
network) provides public information on trials being 
conducted in Australia and elsewhere. In March, 
we welcomed the Minister for Health to the CTC to 
announce a major NHMRC grant to continue and 
develop the ANZCTR’s important work, including further 
enhancements so that registry data can be more easily 
accessed by a variety of users.
Laboratory research is a major new extension of CTC 
activities; for example, blood samples presciently collected 
in the 1990s during the LIPID trial are now being analysed 
for relationships between blood biomarkers and later 
risks of coronary events. Several of these studies were 
presented at the 2012 American Heart Association 
meeting. In the FIELD trial, which recruited 9795 patients, 
blood samples are now being used to identify genetic 
contributions to the complications of diabetes. In our own 
oncology research and as part of the new Sydney Catalyst 
consortium, laboratory studies and genetic identification 
have become a natural companion to our clinical trials; 
with our collaborators, we are pushing beyond the trial 
to integrate the whole research pathway, from bench to 
bedside, with a view to accelerating the application of 
research to outcomes for patients. Our research aiming 
to close the gap between trial evidence and practice 
includes estimating life expectancy and communicating 
this to cancer patients and evaluating diagnostic tests and 
medical technologies.
We have had many successes, increasing knowledge and 
improving outcomes, but clinical trials are becoming 
more costly and more complex, with increasing regulatory 
requirements and as more trials incorporate laboratory 
studies and other translational aspects. We are facing 
up to these challenges, first, in the way we do our own 
research and, second, as part of national efforts to try  
and streamline some of these processes. 
For our part, we constantly improve our methods to 
make trials more efficient and to maximise the evidence 
they produce. Clinical trials are important, not just for 
identifying better treatments, but for finding new uses 
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Directors' report
for current treatments and weeding out ineffective 
treatments — saving money and preventing harm. Trial 
evidence sorts out the good from the bad, and without it 
meaningful advances in health care will not be realised. 
Externally, we contribute to the national and international 
debates about the future direction of research. The rising 
cost of health care is in part driven by the discovery of new 
treatments and the associated cost of clinical trials.  
Non-commercial trials often rely on scarce public grants, 
so many worthwhile projects are not undertaken. 
However, it should be possible to undertake more 
clinical trials at no extra cost to the health system by 
incorporating them into health care delivery. In many 
cases the costs are repaid when treatments proven 
ineffective become no longer funded, and overall, they  
can be more cost-effective than some treatments 
currently funded. To this end, in May the CTC participated 
in the MJA Clinical Trials Research Summit, at which 
leaders in government, industry representatives, 
consumer groups and health professionals met with 
researchers from trial investigator networks to work 
toward strengthening and improving investigator-
initiated research in Australia. The meeting lent 
momentum to new ideas about integrating trials into 
health care, new funding models, designing studies 
incorporating new technologies, and building national 
capacity to support trials research.
As we move into 2013, we will maintain our drive to 
support the integration of clinical trials’ research into 
routine health care. At the CTC we are always aware that 
our ultimate goal is the value of research to patients. We 
will continue to look at how best to use this research to 
answer important clinical questions, and so improve the 
outcomes for patients in Australia and elsewhere.
ctc executive  
CTC operations and research are led by the Executive  
(L to R): John simes, director; Wendy Hague, clinical  
trials program director; tony Keech, deputy director; and 
Kim russell-cooper, general manager.
professor John simes is the foundation director of 
the CTC and represents the CTC on many national 
and international committees. He has for many years 
championed the need for evidence-based clinical research.
professor Anthony Keech is Professor of Medicine, 
Cardiology and Epidemiology at the University of Sydney. 
He is chairman of the international FIELD study on heart 
disease and diabetes and directs the CTC’s research 
program.
dr Wendy Hague is primarily responsible for the 
successful conduct of the CTC’s large-scale, multicentre 
clinical trials and ensuring that trials systems, procedures 
and methods are of the highest standard. 
Kim russell-cooper works with the CTC executive, 
managers and research staff to improve the business 
process in the areas of clinical trial research governance, 
risk assessment, financial planning, management and 
reporting.
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Aspirin treatment is an inexpensive way  
of preventing thrombosis (Aspire)
The international ASPIRE study was completed in 2012. It showed that patients 
who have had a deep vein thrombosis or pulmonary embolus can benefit from 
low-dose aspirin. 
Recurrence is a serious risk for people who have suffered a blood clot in a 
leg (deep vein thrombosis) or lung (pulmonary embolism). Anticoagulant 
treatment, such as with warfarin, comes with the inconvenience of frequent 
blood tests and the risk of bleeding. Now, low-dose aspirin has been shown 
to be an alternative to continuing anticoagulation. It is a simple, inexpensive 
treatment that could prevent thousands of patients from experiencing recurrent 
clots each year and may lead to substantial health care savings in Australia 
and worldwide. It is likely that this treatment will be adopted into practice 
internationally.
All the 822 ASPIRE participants had suffered a deep-vein thrombosis or 
pulmonary embolism that occurred for no particular reason (unprovoked 
venous thrombosis) and had completed about 6 months of anticoagulant 
treatment (generally with warfarin). Participants were randomly allocated 
to receive either low-dose enteric-coated aspirin 100 mg daily or a matching 
placebo. On average, participants were followed up for three years.
John simes, rebecca Mister, adrienne Kirby, Wendy Hague;  
CtC members of the asPire executive committee
6 
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Preventing cardiovascular disease
‘Many patients discontinue warfarin therapy after 6 or 
12 months of treatment due to the inconvenience of regular 
blood tests and the increased risks of serious bleeding 
putting them at high risk of recurring thrombosis.
‘Aspirin reduces the risk of important blood clotting events 
including recurrent VTE, myocardial infarction, stroke, and 
cardiovascular death. We now have clear evidence that 
aspirin benefits patients who are unable or do not wish to 
continue warfarin in the long term.’
—dr tim Brighton, co-principal investigator of asPire  
(with Professor John eikelboom)
The study results were consistent with the findings of an Italian study, 
WARFASA. The investigators of ASPIRE and WARFASA cooperated when the 
trial was being planned; they harmonised the protocols of both studies to 
have similar eligibility criteria and outcomes. The combined results of the two 
trials have shown clear and consistent evidence that aspirin prevents recurrent 
thrombosis. 
ASPIRE began in 2003 as an investigator-initiated study. It was conducted 
by the CTC and investigators in Australia, New Zealand, India, Singapore and 
Argentina. National coordinating centres in India (St John’s Medical College and 
Research Institute, Bangalore) and Argentina (Estudios Clínicos Latinoamérica 
International, (ECLA) Rosario) were responsible for coordinating the study in 
these countries. It was supported by project grants from the National Health 
and Medical Research Council, the New Zealand Health Research Council, the 
Australasian Society of Thrombosis and Haemostasis and Bayer HealthCare, 
Germany. 
The results were published in the New England Journal of Medicine and presented 
at the Late Breaking Clinical Trials session at the American Heart Association 
meeting in November.9,154
Professor John simes
‘These results suggest that 
aspirin prevents about one 
third of recurrent blood 
clot events. For every 1000 
patients treated for 1 year, 
aspirin can be expected 
to prevent about 20 to 
30 episodes of recurrent 
major thrombotic events 
at the cost of about  
3 significant bleeding 
episodes. ‘
 NHMRC CLINICAL TRIALS CENTRE: 2012 RESEARCH REPORT 7
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ongoing studies in diabetes  
from FieLd data
The FIELD (Fenofibrate Intervention and Event Lowering 
in Diabetes) study was an international multicentre trial, 
initiated and coordinated by the CTC, investigating the 
use of fenofibrate to reduce the risk of coronary heart 
disease in people with type 2 diabetes. The FIELD dataset 
is still being used to answer questions that will benefit 
diabetes patients.
A major contributor to the disease burden of type 2 
diabetes is stroke in its various forms, but which factors 
raise the risk of stroke has been controversial. For 
example, some studies, but not all, have shown that 
the risk decreases with age beyond the fifties. The large, 
well-documented database of the FIELD cohort, 9795 
patients, allowed the investigators to analyse the factors 
associated with a risk of various subtypes of stroke in 
these patients. They found that most strokes were caused 
by an interruption to blood flow rather than bleeding. 
The cause of stroke was most commonly disease in the 
small arteries.Those at highest risk were older people. 
This detailed information on types of stroke and related 
risk factors will help clinicians quantify risks of stroke for 
individual patients.40
Clinical guidelines for the FIELD study drug, fenofibrate, 
have recommended caution in using it for patients 
with impaired kidney function. A substudy, published in 
Diabetes Care, assessed the benefits and safety of the drug 
in cases of mild or moderate renal impairment.114 This 
analysis showed that using the drug did not lead to kidney 
disease and that it was safe for these patients, suggesting 
that the guidelines may be too restrictive. Another 
study focused on the safety of fenofibrate therapy with 
respect to thromboembolism, because fenofibrate raises 
the level of homocysteine. It was found that naturally 
occurring levels of homocysteine are related to risk of 
thromboembolism and that fenofibrate treatment was 
associated with a higher risk of thrombosis in patients 
with high homocysteine at baseline.42
Most of the FIELD survivors from Australia and New 
Zealand are still providing follow-up data through their 
responses to regular questionnaires and data linkage. 
Around 1750 Australian participants had blood samples 
collected late in 2012. Laboratory analyses of the samples 
taken during the trial and its follow-up will allow the 
investigators to determine biological and genetic 
markers of the risks of cardiovascular disease and other 
complications of type 2 diabetes (p.20).
li Ping li, manager of 
the Field trial follow-up
Mark donoghoe, rachel 
o’Connell and anne-sophie 
veillard, biostatisticians for 
Field studies
CardiovasCular suBstudies
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Preventing cardiovascular disease
Lipid (Long-term 
intervention with 
pravastatin in  
ischaemic disease)
Taking a statin drug to lower 
cholesterol to prevent heart attacks 
is now common in Australia and 
elsewhere. The CTC’s LIPID study 
was one of the key trials providing 
evidence on the benefits of statin 
therapy and one of the largest 
clinical trials undertaken in Australia, 
involving 9014 patients from 
87 hospitals in Australia and  
New Zealand. 
Most of the survivors provided  
follow-up data through their 
responses to regular questionnaires 
sent to them until 2007. Mortality 
and cancer data have been obtained 
for nearly 9000 patients, 97% of 
the original cohort, through linkage 
with death and cancer registers. CTC 
researchers have analysed these data 
to assess the effect of pravastatin 
treatment 10 years beyond the trial 
by comparing the patients originally 
assigned pravastatin with those 
originally assigned placebo. The 
protective effect of pravastatin is still 
detectable, although diminishing, and 
there is no evidence that pravastatin 
increases the risk of cancer.
In addition to the main presentation 
of these results at the American Heart 
Association Scientific Sessions in 
Los Angeles in November,170 the work 
was selected for the AHA International 
Forum after the abstract had been 
identified as one of the best submitted 
from Australia. A special session was 
dedicated to Australia to spotlight 
important aspects of its cardio-
vascular research.
BioMArKer stUdies
The LIPID managing group, now 
including laboratory scientists, has 
been using blood samples collected 
from LIPID patients in the 1990s to 
investigate the associations between 
levels and changes of various blood 
components and the risk of heart 
disease outcomes. Various results 
were presented at international 
meetings in 2012, including the 
finding that midregional pro-
adrenomedullin may help to identify 
patients at risk of future events, 
especially heart failure.168
international meta-
analysis of cholesterol 
lowering to prevent 
cardiovascular events
The CTC and the Clinical Trials 
Service Unit at the University of 
Oxford have collaborated for over 
20 years to operate the secretariat of 
the Cholesterol Treatment Trialists’ 
Collaboration (CTTC). The purpose 
of the collaboration is prospective 
meta-analysis of data from the many 
patients worldwide in coronary heart 
disease prevention trials. 
The most recent studies have 
analysed data from 27 trials involving 
175 000 participants. Data from the 
LIPID study were included. A study 
published in The Lancet showed that, 
in people with a 5-year risk lower than 
10%, statin therapy reduces the risk 
of major cardiovascular events, which 
is related to lowering the level of LDL 
cholesterol. Per 1000 people treated 
with a statin over 5 years, 11 major 
cardiovascular events are avoided 
for each 1.0 mmol/L reduction in 
LDL cholesterol.73 A separate analysis 
showed that statin therapy did not 
influence the incidence of cancer 
or the rate of death from cancer, 
even among those whose LDL levels 
became very low.18
These 2012 findings, in the context of 
results from trials, such as LIPID, and 
CTTC meta-analyses over the past 
decade, have produced compelling 
evidence that lipid-lowering statin 
therapy reduces cardiovascular events, 
leading to new recommendations 
that clinical guidelines advocate statin 
treatment for patients with lower  
LDL cholesterol as well as those at 
high risk.
Wendy Hague, clinical trials program 
director and member of the liPid  
study group
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A joint initiative to improve health in high-priority areas
the ctc and its collaborators at the Boden institute of obesity, Nutrition, exercise and eating 
disorders (BioNe) and Macquarie University will begin a new program of research in 2013, funded  
by a five-year program grant from the NHMrc. 
it will bring together a multidisciplinary team of clinicians, epidemiologists, triallists, biostatisticians 
and health economists and national and international collaborative networks of investigators to 
tackle major health care questions in high-priority health areas.
the research program will focus on research questions promising the most benefit for future clinical 
practice and health policy. the research strategy focuses on diseases having significant mortality and 
morbidity and where advances will have substantial influence: in particular cancer, cardiovascular 
disease, diabetes, obesity and neonatal diseases. the program will integrate trials with translational 
basic science and further develop methods of assessing and applying clinical trial evidence to 
individual patients and to populations.
cHieF iNvestiGAtors oF tHe NeW proGrAM
Top row: John simes, Anthony Keech, val Gebski and Martin stockler 
Bottom row: ian caterson (BioNe), stephen colagiuri (BioNe), deborah schofield and  
ian Marschner (Macquarie and ctc)
Preventing cardiovascular disease
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The CTC’s neonatal group conducts large 
multicentre trials covering important questions 
affecting the health, survival and future prospects 
of newborn babies. Data from these trials 
contribute to international meta-analyses of data 
from thousands of patients.
the Australian placental transfusion study 
(Apts) 
APTS is determining whether a 60-second delay 
in clamping and cutting the umbilical cord can 
improve the baby’s blood flow to the brain and 
gut reducing the need for donor blood and reduce 
rates of infection, retinopathy, poor growth, death 
and disability in babies born more than 10 weeks 
early. This trial is continuing. 
Benefits of oxygen saturation targeting,  
trial ii (Boost ii) 
BOOST II is ascertaining which of two oxygen 
saturation ranges is better for very premature 
babies. Oxygen is the most common therapy for 
preterm infants. Doctors and nurses do not know 
the safest and most effective level of oxygenation 
for these babies. Higher oxygen levels may increase 
retinopathy of prematurity and respiratory 
problems, but lower oxygen levels may affect other 
long-term outcomes. The trial will be completed 
in 2013. 
 Alpana Ghadge,  
manager of Boost ii
NeoNAtAL MetA-ANALyses
As a member of several 
international collaborations 
in neonatology, the ctc 
coordinates and participates 
in meta-analyses designed to 
turn trial data into evidence. 
data from several trials can 
be combined in an individual-
patient-data meta-analysis 
where large numbers of patients 
are needed for a definitive 
statistical analysis. two neonatal 
groups have recently published 
their protocols.20,132
the ctc’s neonatal trials
Lucille sebastian,  
manager of Apts
NeoNAtAL triALs
William tarnow-Mordi (pictured right) attended the patient 
safety summit of the patient safety, science & technology 
Movement, whose goal is ‘zero preventable deaths by 2020’.  
He moderated the neonatal panel, and met the keynote 
speaker, president Bill clinton (pictured left).
As a commitment arising from the summit, an international 
alliance for pulse oximetry screening in newborns will be 
supported by the WiNNer centre for Newborn research and 
the ctc, which aim to work with others to ensure that all 
babies can benefit from earlier diagnosis of critical congenital 
heart disease, neonatal sepsis, pneumonia and pulmonary 
hypertension through routine pulse oximetry before discharge.
dr lisa askie, director of systematic 
reviews and a leader in meta-analyses  
in neonatal disorders
 ARNO MASSEE/SCIENCE PHOTO LIBRARy
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cancer trials
Gastrointestinal cancer (AGitG trials)
The CTC is the coordinating and statistical centre for the Australasian Gastro-
Intestinal Trials Group (AGITG), a national network of gastrointestinal cancer 
investigators. The AGITG-CTC collaboration has now been continuing for over 
20 years, improving the treatment and outcomes of people with gastrointestinal 
cancers, that is, cancers of the oesophagus, stomach. liver, gall bladder, pancreas 
and bowel. New concepts for trials are developed by this collaboration.
During 2012 the CTC’s work included participating in an external review of 
AGITG in May, presentations and publications from completed trials, significant 
work with AGITG on major flagship trials, particularly INTEGRATE and TOPGEAR 
in gastric cancer, launching new trials, and further development of new 
proposals for trials opening in 2013. In 2012, 265 patients were recruited to 12 
clinical trials.
A 5-year NHMRC Project Grant was obtained to support the ongoing conduct of 
the TOPGEAR trial, including work with international collaborators the National 
Cancer Institute of Canada and the European Organisation for Research and 
Treatment of Cancer. 
In 2012, results from several major collaborative trials were published, including 
the international ESPAC-3 study in JAMA.142 Data from the MAX trial were 
analysed in a substudy that showed that bevacizumab and capecitabine 
combined was safe, effective and well tolerated in patients aged over 75.87 
This evidence on treatment for an under-researched group will be useful for 
clinical practice. A collaboration of the Trans-Tasman Oncology Group with 
AGITG published the results of a trial comparing a short course of preoperative 
radiotherapy with a longer course for patients with rectal cancer; after 3 years no 
difference in rates of distant recurrence, survival, or late toxicity were detected.144 
Twenty-one oral and poster presentations of current AGITG studies were 
presented at major international and national meetings in 2012. 
danielle Ferraro and dirkje sommejier, medical oncologists  
and CtC clinical research fellows for agitg trials
Professor John 
Zalcberg, chairman 
of the australasian 
gastrointestinal  
trials group
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Improving quality of life and survival for people with cancer
Urogenital cancer 
(ANZUp trials)
The CTC collaborates with the 
Australian and New Zealand 
Urogenital and Prostate Cancer Trials 
Group (ANZUP). Current trials are 
investigating treatments for testicular, 
kidney and bladder cancers. 
Testicular cancer, usually as germ-cell 
tumours, is the most common cancer 
in young men in Australia. Although 
most patients do well, many of 
those with intermediate- and poor-
prognosis disease relapse and die 
despite treatment. Mechanisms of 
chemotherapy resistant germ-cell 
tumours are not well understood. 
Accelerating chemotherapy by 
administering treatment 2-weekly 
rather than 3-weekly may increase 
cure rates without significant 
additional toxicity or cost. The 
ANZUP-CTC collaboration conducted 
a very successful phase II trial, 
Accelerated BEP, into the feasibility 
and tolerability of an accelerated 
dose-dense treatment regimen and 
presented the results at the American 
Society of Clinical Oncology meeting 
in 2012.169 The results of this trial, and 
other evidence, supported the case for 
a large phase III trial of this treatment. 
With new funding from Cancer 
Australia, the trial will commence 
recruiting patients from Australia, the 
UK and the USA in 2013.
Bacillus Calmette-Guérin (BCG), 
an immunotherapy related to 
tuberculosis vaccine, is an effective 
treatment for bladder cancer when 
introduced locally into the bladder 
after surgery on the tumour. Some 
patients do not respond to this 
treatment, and it is uncertain whether 
adding chemotherapy improves 
their prospects. In 2012 the group 
published a meta-analysis of current 
evidence on this topic.48 Their results 
indicated that adding chemotherapy 
to the treatment for some patients 
should be tested in a clinical trial. 
In 2013, they will commence a 
large phase III trial trial of adding 
mitomycin C to BCG as adjuvant 
intravesical therapy for high-risk, 
non-muscle-invasive bladder cancer, 
with initial funding from Cancer 
Australia.
Gynaecological cancer 
(ANZGoG trials)
The CTC is the coordinating 
centre for the Australia New 
Zealand Gynaecological Oncology 
Group (ANZGOG), the Australian 
investigator group for cancers 
involving the female reproductive 
system. ANZGOG is a member of 
the Gynecological Cancer Intergroup 
(GCIG), the peak international body 
in this field.
2012 was an outstanding year for the 
group, with 95% of the 386 recruited 
patients coming from ANZGOG-CTC 
home-grown trials.
The CTC and ANZGOG are 
collaborating on the CTC’s first  
phase I study (ANZGOG-1103), 
which is adding a new investigational 
agent to the standard treatment 
of carboplatin and gemcitabine for 
treatment of relapsed ovarian cancer. 
The CTC and ANZGOG lead the 
OUTBACK trial, which is investigating 
the benefit of adding chemotherapy 
to standard chemoradiation 
treatment for high-risk cervix cancer. 
OUTBACK is also open to recruitment 
in the US, supported by the National 
Cancer Institute. The current status of 
the trial was presented in June.189 
Symptom Benefit is another 
highly successful international 
collaboration led by ANZGOG-
Professor ian davis, Monash 
university, is chair of anZuP, the 
australian cooperative group for 
urogenital trials
Julie Martyn, associate oncology program 
manager for gynaecological trials, and 
Kerri Carlton, trial coordinator
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MANAGiNG cANcer triALs
‘The diversity of my different roles (data 
manager, trial coordinator, manager) over 
the last 10 years in the therapeutic areas 
of early breast cancer and lung cancer has 
allowed me to extend my capabilities and 
knowledge through engagement with a 
wide range of staff who individually bring 
their own unique experience to each trial. 
Oncology staff come from a multitude of 
backgrounds, so managing these teams is 
a synergy of the desire to run the trial as 
effectively and efficiently as possible and 
using all our varying experience and skill sets 
together, to achieve a well coordinated trial. 
‘The most rewarding aspect since my 
appointment as an associate oncology 
program manager in 2007 is that it is a 
multifaceted role — including protocol 
development, budget forecasting, grant 
applications, project management, and 
managing teams— so I experience the 
life cycle of a trial from many angles with 
talented individuals, both CTC staff and  
our external collaborators.’
— Xanthi Coskinas, associate oncology  
program manager for lung cancer trials
CTC, with participation from nine GCIG groups, on the 
benefit of palliative chemotherapy in advanced ovarian 
cancer. PARAGON is a study of aromatase inhibitors 
across a range of potentially hormone-responsive 
gynaecological cancers, again led by ANZGOG-CTC and 
open internationally. 
The CTC is the statistical centre for the now completed 
international ovarian cancer CALyPSO trial, which found 
that carboplatin and liposomal doxorubicin was more 
effective and better tolerated than the standard treatment. 
The new therapy has become the standard of care for 
patients with recurrent ovarian cancer. Statisticians 
and others at the CTC have continued to participate in 
CALyPSO substudies and methodological analyses.1,10,37,123
Data from CALyPSO and 13 other trials comprising 
nearly 17 000 patients were used in a meta-analysis to 
investigate how well progression-free survival predicts 
overall survival in patients who had platinum therapy for 
epithelial ovarian cancer. The two outcomes were highly 
correlated, indicating that progression-free survival could 
be used as a surrogate outcome for survival in future 
trials, a methodological advance that should lead to more 
efficient trial design.207
Lung cancer (ALtG trials)
The CTC collaborates with the Australasian Lung Cancer 
Trials Group (ALTG), the national investigator group for 
lung and thoracic cancer trials.
In the ALTG’s homegrown flagship trial, NITRO, patients 
with non-small-cell lung cajncer are given a nitroglycerin 
patch or a placebo in addition to their chemotherapy.  
The effect on progression-free survival and other 
outcomes is being assessed. Recruitment has reached 
50% in just 3 years. A prospective meta-analysis is being 
planned with the Netherlands Dutch Association of Chest 
Physicians (NVALT), which conducted a similar trial. In 
2013 the ALTG-CTC team will be working with NVALT to 
incorporate 10 Dutch sites into the NITRO trial: the first 
ALTG-CTC-led international collaboration in lung cancer.
In 2012, the group presented results of a phase II trial 
of a vascular disrupting agent, BNC105P, for advanced 
malignant pleural mesothelioma. Tumours did not 
respond to this new treatment, so recruitment was 
ceased, although biomarker analyses are continuing.192
14 
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Improving quality of life and survival for people with cancer
tumours of the brain and nervous system  
(coGNo trials)
The CTC is the coordinating centre for the Cooperative Trials Group for 
Neuro-Oncology (COGNO). 
COGNO-CTC have been conducting CABARET, a phase II study of a new 
treatment for glioblastoma multiforme, an aggressive malignant tumour for 
which there is no accepted standard management after disease progression. 
The study is comparing bevacizumab treatment alone with a combination 
of bevacizumab and carboplatin. It incorporates a prospective analysis of 
CogState neurocognitive testing for patients with brain tumours. Accrual to 
the first part of the trial is complete. The investigators presented feasibility  
and safety findings at several international meetings in 2012.164,165,166
COGNO held its annual scientific meeting in Brisbane in August. The theme 
was ‘Neuroimaging: novel approaches for glioma’, which took in sessions on 
neuroimaging, low-grade gliomas, translational research and comprehensive 
care. Included in the program was a joint symposium with the Medical 
Oncology Group of Australia (MOGA) on contemporary management of 
brain metastases.
COGNO had a concept development workshop in 
May, which generated ideas for new trials for the 
group, and a strategic planning day in December, 
confirming COGNO’s mission and aims and laying 
the groundwork for the development of a plan for 
the next 5 years.
dr Kathryn Field, principal investigator of CaBaret 
(randomised phase ii study of carboplatin and 
bevacizumab in recurrent glioblastoma multiforme)
coordiNAtiNG  
cLiNicAL triALs iN  
NeUro-oNcoLoGy
‘Working at the CTC is a 
little like being a juggler, 
sometimes with all three 
balls in the air at once. No 
two trials are alike, and being 
able to coordinate a complex 
clinical trial is a fantastic 
challenge. It provides an 
opportunity to work with 
leading researchers and 
scientists at the forefront 
of their fields, with the 
potential to change current 
practice and improve 
outcomes for patients with 
cancer. 
‘In my role at the CTC I have 
been fortunate to have seen 
a trial from the early stage 
of protocol development 
through its lifespan. This 
has allowed me to develop 
diverse skills and knowledge 
which will be invaluable for 
future trials.’ 
— Kate sawkins, oncology clinical 
trial coordinator, Cooperative trials 
group for neuro-oncology (Cogno)
Brain cancer glial 
cells. glioblastomas 
are the most 
common and most 
aggressive form of 
brain tumour. they 
are derived from 
glial cells
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current studies in breast cancer (with rAcs)
sNAc1
The SNAC1 trial is a study, now in long-term follow-
up, of surgery for women with early breast cancer. It is 
determining whether sentinel lymph node biopsy (with 
axillary clearance only if the sentinel node is positive) is 
less damaging than immediate axillary clearance, and 
whether the cancer-related outcomes are equivalent. 
Recruitment finished in 2005, with 1088 participants.
Results from SNAC and other trials of sentinel node 
biopsy have been used in a decision-model analysis of 
the effectiveness and cost-effectiveness of this approach 
to diagnosis and treatment, which was published in the 
British Journal of Cancer.121
sNAc2
The SNAC2 trial is an extension of SNAC1. The primary 
objective is to determine whether sentinel-node-based 
management, compared with axillary clearance, increases 
the risk of locoregional recurrence and in particular, 
axillary recurrence, in any subgroup of women. This study 
includes women with larger tumours and those with 
multiple primary tumours in the same breast. SNAC2 
opened to recruitment in 2006 with the target of 1012 
women. The trial continues to recruit patients from 
almost 40 sites across Australia, New Zealand, Singapore 
and Hong Kong.
costs of treatment ($) used in the decision model analysis of 
effectiveness and cost-effectiveness in early breast cancer121
AXILLARy CLEARANCE PROCEDURE 5 576
SENTINEL LyMPH-NODE PROCEDURE 4 206
AXILLARy CLEARANCE  
 AFTER SENTINEL LyMPH NODE POSITIVE
7 771
ADJUVANT THERAPy FOR EARLy BREAST 
CANCER
 Radiotherapy 5 130
 Chemotherapy 16 160
 Endocrine therapy 10 961
 Herceptin therapy 64 033
 Annual follow-up 254
 Physiotherapy 60
LOCAL RECURRENCE 7 658
AXILLARy RECURRENCE 24 556
DISTANT METASTASES (ANNUAL) 24 340
END OF LIFE COSTS 29 616
DEATH FROM OTHER CAUSES 8 659
estimates of breast cancer spread are an important  
supplement to clinical trial data
An epidemiological study by sally Lord and colleagues estimated the incidence of metastatic cancer 
developing within 5 years in women initially diagnosed with non-metastatic breast cancer. the 
researchers were particularly interested in women aged over 70 years and women from regional and 
remote areas, groups not well represented in clinical trials. they found that women were more likely to 
develop metastases if their disease had spread beyond the breast at diagnosis, if they were under 50, or if 
they lived in a lower socioeconomic area. Metastatic cancer appeared most often in the second year after 
their initial diagnosis.67
An editorial in the Medical Journal of Australia commented: ‘this is the first population-based 
Australianreport on this subject … and will inform discussions with Australian women newly diagnosed 
with breast cancer, for whom the issue of possible cancer spread is personal and vital. the article is 
important for its headline findings, its methods and its implications for clinical care and the collection of 
meaningful data.’
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Improving quality of life and survival for people with cancer
New research using data 
from clinical trials helps 
patients and clinical 
practice
proGNosis
The expected survival time of patients 
with cancer can be uncertain, with 
many factors contributing, such 
as the size of a tumour, cancer 
biomarker levels, and the number of 
sites of metastasis.
To respond to a need for accurate 
and reliable information on expected 
survival for patients with advanced 
ovarian cancer, the investigators 
of the CALyPSO trial and CTC 
statisticians developed a nomogram, 
which assigned points for values of 
clinical factors in such patients treated 
with platinum chemotherapy. This 
was an extension of previous research 
into estimating progression-free 
survival time. The new nomogram, in 
simplified form, was validated on data 
from two other ovarian cancer trials. 
The nomogram, with 6 prognostically 
significant factors, was able to 
predict survival accurately enough 
to be useful to clinicians counselling 
patients.65 After further validation,  
it may also be used to stratify patients 
in clinical trial analysis.
In another study on predicting 
survival, this time in renal cancer, 
CTC researchers used the knowledge 
that temsirolimus is an effective 
treatment for renal cancer and that 
it is also associated with increases in 
serum cholesterol, triglyceride, and 
glucose to explore the hypothesis 
that the two effects were related. 
The study used data from patients 
randomised to temsirolimus or 
interferon in the Global Advanced 
Renal Cell Carcinoma trial to show 
that increase in cholesterol (but not 
triglycerides or glucose) predicts 
the efficacy of temsirolimus in these 
patients.64 Measuring the cholesterol 
increase may be a way to screen new 
treatments in clinical trials.
 
Continued on page 18...
Belinda Kiely, Katrin sjoquist and Chee lee are medical oncologists who undertake 
research bridging clinical trials and clinical practice
BeNcH to Bedside 
oNcoLoGy  
trANsLAtioNAL reseArcH
the ctc works in collaboration 
with sydney catalyst (p. 19) to 
undertake translational cancer 
research, in which researchers 
collaborate to apply laboratory 
discoveries to treatment and care 
of patients and then to improve 
the use of research evidence 
in routine clinical practice. 
this approach will shorten the 
time between new scientific 
discoveries and ultimately  
using them to improve the 
survival and quality of life  
of cancer patients.
Most trials coordinated at 
the ctc include an option 
for patients to consent to 
biological samples being used 
in specific research projects 
or being banked for future 
research. samples of blood or 
tumour tissue are collected, then 
analysed in the laboratory for a 
range of individual biomarkers 
that may correlate with a 
patient’s clinical outcomes or 
predict the response of a patient 
to a treatment.
in the new iMpAct trial, a 
collaboration with the AGitG, 
sydney catalyst, and the 
Australian pancreatic cancer 
Genome initiative, patients are 
being screened for entry on the 
basis of their genetic make-up.190 
this information will be used 
to match individuals to specific 
therapies, with the hope of 
improving their response  
to treatment.
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can Australia afford new cancer treatments?
dr deme Karikios is undertaking research for a phd thesis, ‘the costs 
and effects of new anticancer drugs’.
in 2012 he presented an investigation of the price of drugs over a 
decade.176 He and his colleagues found that the expenditure by the 
pharmaceutical Benefits scheme had increased 8-fold and its cost 
per prescription had quadrupled. such rising costs and prices may 
become unsustainable.  
one solution to the rising costs might be better targeting of effective 
treatments for individual patients, a focus of current oncology 
research at the ctc and elsewhere. 
coMMUNicAtioN oF LiFe expectANcy to pAtieNts (...from page 17)
Most people with advanced cancer want to know how their illness will affect their life expectancy, a difficult task 
for their doctors. 
Median life expectancies for various cancers are available from clinical trials, but a single point estimate of 
survival is not helpful for patients, especially as it does not convey the concept or the hope that an individual 
patient may survive much longer. 
Oncologists from the CTC have been carrying out a series of studies that help clinicians to estimate how long a 
patient might live and explain the estimate to patients in a meaningful way.58,59 They have proposed providing 
estimates of the best case, worst case, and typical scenarios for survival as a useful way of communicating life 
expectancy. A study presented in 2012 examined medical oncologists’ estimates in relation to real survival 
times and concluded that the oncologists estimated these three scenarios accurately.177,178,179 To explore the 
patients’ side of the story, the researchers then surveyed patients attending oncology clinics, asking them how 
a hypothetical cancer patient would respond to information about survival. Most preferred the presentation of 
best case, worst case, and typical scenarios to knowing only the median survival time.59,181
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Improving quality of life and survival for people with cancer
sydney catalyst: the translational cancer research centre  
of central sydney and regional NsW
sydney catalyst is a multidisciplinary and multi-institutional endeavour, established in 2011 with core funding 
from the cancer institute NsW and based at the ctc. it brings together teams of clinicians and researchers from 
across NsW with the purpose of facilitating rapid translation of scientific discoveries into clinical policy and 
practice to improve patient outcomes.
in 2012, sydney catalyst commenced its t2 translational flagship program, defining Knowledge translation 
in cancer (in lung cancer, colorectal cancer, melanoma and supportive care), and also in 2012 its first t1 
translational flagship program, the iMpAct trial (individualised Molecular pancreatic cancer therapy ) was 
highlighted in Nature news, 21 March issue. sydney catalyst awarded to members pilot and seed funding for 
four research initiatives, a full three-year phd scholarship and several postgraduate top-up scholarships and 
travel and education awards. other members were recipients of 5-year cancer institute NsW translational 
program grants. 
sadly, sydney catalyst lost one its founding members, prof rob sutherland, FAA, Ao, who died in october.  
He is missed by sydney catalyst and the oncology research community.  
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predicting type 2 diabetes complications to  
improve risk assessment and treatment
New CTC research is identifying genetic contributions to the complications of 
diabetes, such as heart disease, stroke, eye disease and kidney disease. 
Telomeres, which cap the ends of chromosomes and protect them during cell 
division, are the focus of this NHMRC-funded research. Telomeres tend to 
shorten with age, and shorter telomeres are associated with vascular risk factors, 
inflammation and oxidative stress, and vascular disease. 
The study is investigating the relationships among genes, telomeres and 
diabetes by looking at DNA variation in patients from the CTC’s completed 
FIELD trial (p.8) and, in the NHMRC-funded follow-up studies, also 
investigating whether the blood-fat-modifying drug fenofibrate reduces the rate 
of  telomere shortening.
Results of a pilot study on patients with type 1 diabetes were presented at the 
meeting of the American Diabetes Association.174 It was found that age-related 
telomere shortening was worse in people with diabetes, suggesting accelerated 
ageing. Telomere length correlated 
with the duration of diabetes, but was 
not related to diabetes complications 
or risk factors. In people without 
diabetes, telomere length correlated 
with inflammation, renal function 
and vascular health. Age, diabetes 
and C-reactive protein levels were 
independent determinants of 
telomere length.
rApid study:  
rNA-based Analysis  
for prediction of  
islet death
Most people with type 1 diabetes 
have lost more than 50% of their 
insulin-producing cells by the time 
they start showing any symptoms. 
There is therefore an urgent need 
to identify novel biomarkers that 
can help in diagnosis at even earlier 
stages of the disease. The aim of 
RAPID is to assess noncoding RNA- 
and micro RNA-based biomarkers 
of diabetes. 
The knowledge gained from the 
RAPID study will inform medical 
researchers as to whether the 
development and progression of 
type 1 diabetes can be predicted, 
provide tests to monitor treatment 
strategies, and guide the 
development of new treatments to 
lessen the burden of diabetes. 
The collaboration, led by Associate 
Professor Anand Hardikar, received 
an Australian Future Fellowship 
from the Australian Research 
Council in 2012.
raPid research team sarang satoor, 
Wilson Wong, anandwardhan Hardikar 
and Mugdha Joglekar
susan Mclennan, surya sutanto, alicia Jenkins, anandwardhan Hardikar, Wilson Wong, 
stephen twigg and anthony Keech collaborating on genetic research in diabetes
diABetes BioMArKer reseArcH 
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Australian New Zealand 
clinical trials registry 
The ANZCTR is an online database that provides public 
information on trials being conducted in Australia, 
New Zealand and some other countries. Its aims are 
to maximise patient participation in trials, minimise 
unnecessary duplication of research and enable a reliable 
assessment of clinical research evidence by ensuring all 
relevant trials are known. 
The Australasian registry, administered at the CTC, was 
one of the first World Health Organization-recognised 
primary registries of clinical trials.
The ANZCTR improves the efficiency and value of 
Australian clinical trials research by helping to increase 
trial participation and showing the current status of 
clinical research. It allows policy makers and researchers 
to identify potential gaps between current trials research 
activity and health priorities. For example, the register 
shows not only which trials are being conducted, but also 
where trial activity is deficient. A study presented in 2012 
used estimates of the burden of disease in various health 
areas and compared these with the planned recruitment 
of patients in these areas.182 Planned recruitment to 
asthma, obesity and diabetes trials was less than half 
that expected, and for asthma and obesity the number of 
registered trials was also lower than expected.
The number of trials registered by the ANZCTR now 
stands at 7500.
represeNted  
oN tHe ANZctr  
Advisory coMMittee
•	 chief Medical officer of Australia
•	 University of sydney
•	 international committee of Medical 
Journal editors
•	 Australian Health ethics committee
•	 therapeutic Goods Administration 
•	 National Health and Medical 
research council
•	 New Zealand Health research 
council
•	 pharmaceutical industry
•	 consumers
the Minister for Health, the Hon. tanya Plibersek (pictured 
above), announced a grant of $2.1 million to the anZCtr 
from the nHMrC.
the grant is enabling the registry to undertake research 
into the functions and use of the registry and to make 
access easier for a variety of users, especially patients and 
their families and friends. 
the Minister’s announcement at the CtC was attended 
by many. shown with the Minister are Professor Warwick 
anderson, chief executive officer, nHMrC; associate 
Professor lisa askie, manager, anZCtr; John stubbs, 
consumer representative; Professor John simes; dr Michael 
spence, vice-chancellor, university of sydney
evideNce For cLiNicAL prActice ANd poLicy 
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 ctc coNtriBUtes to tHe WorLdWide 
cocHrANe coLLABorAtioN
‘I work closely with the joint coordinating 
editors on setting policies and procedures 
for the Breast Cancer Review Group and 
managing the editorial process for all its 
incoming Cochrane titles, protocols and 
reviews. The key word is collaboration, 
and as part of this, we provide extensive 
and ongoing support to our authors, who 
have varied experience and expertise. 
‘I enjoy being part of the entire Cochrane 
process, where we’re committed to 
developing high-quality systematic 
reviews that can be used and understood 
by a range of people. On a daily basis, my 
role can vary from cross-checking that a 
review complies with Cochrane standards, 
identifying appropriate peer referees, 
and editing and proofreading to finally 
marking up a review for publication.’
— Melina Willson, manager, Cochrane  
breast cancer review group
cochrane collaboration  
groups at the ctc
the cochrane collaboration is an international 
organisation of more than 28 000 health care 
professionals, practising physicians, researchers and 
consumers, which is committed to providing high-
quality public information about the effectiveness of 
health care interventions. 
the ctc is the home of: 
1. the cochrane Breast Cancer review group, which 
coordinates, edits and facilitates the publication of 
reviews of evidence in breast cancer and 
2. the Prospective Meta-analysis Methods group, 
an expert group for methodological development and 
advice. 
Both groups enlist new authors from around the world 
who have a range of expertise and experience. they 
also support and train new authors to allow them to 
undertake systematic reviews.
in 2012, the cochrane Breast cancer review Group 
facilitated the publication of clinically relevant and 
high-priority reviews, which covered (to name a few): 
therapies that target specific receptors on cells  
(for example, trastuzumab) for adjuvant therapy and 
diversity oF NeW AUtHors recrUited By tHe 
cocHrANe BreAst cANcer revieW GroUp  
iN tHe pAst 2 yeArs
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Evidence for clinical practice and policy
 
reviews of new procedures and technologies 
considered for public funding
In Australia, new medical procedures and technologies are funded by the 
taxpayer on the basis of evidence that they are safe, effective and cost-effective. 
Decisions are made by the Minister for Health and Ageing, advised by the 
Medical Services Advisory Committee (MSAC).
A team at the CTC takes part in systematically reviewing the evidence for  
some of these new procedures and preparing reports for the committee.  
The evaluators are supported by an expert advisory group comprising clinical 
experts nominated by the department and MSAC representatives. MSAC  
makes a recommendation to the Minister on the basis of the report.
During 2012, the team developed protocols for the review of several new 
technologies, including radiosurgery for intracranial tumours, intensity-
modulated radiation therapy, image-guided radiation therapy and botulinum 
toxin for urinary incontinence. The team also prepared full assessments of 
holmium:yAG laser enucleation of the prostate (HoLEP) for the treatment of 
benign prostatic hyperplasia149 and fiducial markers to guide external beam 
radiotherapy in prostate cancer.
samara lewis, sally lord and sally Wortley, experts in reviews of new technology
MetHodoLoGicAL GUidANce For  
diAGNostic test evALUAtioN
Before a new diagnostic test is introduced into clinical practice, it must 
be evaluated, not just for its accuracy, but for its ability to change clinical 
management and ultimately improve outcomes. The pathway from a 
new test to better health for patients can be complex, and clinical trials of 
the process are not usually feasible. 
Therefore, studies evaluating tests sometimes use a change in clinical 
management (or some other intermediate outcome, like the time to 
treatment) as the measure of the benefit of a test. CTC researchers in the 
field of diagnostic tests have reflected on the reporting of these studies 
and provided guidance on how this evidence should be reported.103, 104 
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treatment of early breast cancer, 
managing chemotherapy-
related side effects, new 
modes of delivering radiation 
to the breast tissue, surgical 
techniques to optimise wound 
management after breast and 
axillary surgery, and differing 
forms of survivorship care. 
the review findings are 
integrated into national and 
international clinical guidelines, 
such as the clinical Best practice 
Guidelines in Australia, the 
National institute for Health 
and care excellence in the UK, 
and international consensus 
statements, such as those of the 
central european cooperative 
oncology Group for advanced 
breast cancer.
diversity by discipline
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prActicAL AppLicAtioN iN 
HeALtH ANd ecoNoMics
‘As an NHMRC Early Career 
Research Fellow I am 
working to build Australia’s 
first measure of long-term 
multidimensional poverty. 
This will bring Australia 
in line with international 
best practice in this field, 
and will be the first time 
internationally that a 
clinically robust measure of 
health status— one based 
on the SF-36 measure of 
health—has been used in any 
measure of wellbeing.
My work has a strong focus 
on practical applications and 
will influence the way living 
standards are conceptualised 
and measured in this 
country.’ 
— emily Callander, research fellow  
in health economics
Health economics: critical to translating  
research into practice and policy 
As governments face increasing budget deficits and the global financial crisis 
cripples the economies of many first world nations, the competition for funding 
for health care increases. In this environment, a robust economic evaluation of 
the costs and benefits of new interventions is critical to presenting a justification 
for funding.
The health economics team has developed an internationally recognised 
research program which captures the far reaching and potentially substantial 
benefits of improved health not just within, but also beyond, the health system. 
Over the last two years, the health economics team have completed a large scale 
microsimulation model to project the long-term impact (to 2030) of health 
on labour force participation, on family incomes and savings, and the flow-on 
effects for the sustainability of government finances due to impacts on taxation 
revenue and social security payments. The model takes account of disease 
trends such as the increasing prevalence of diabetes, demographic change 
including population ageing, policy trends such as increasing superannuation 
coverage and contributions, and labour trends such as rising female labour 
force participation. The model was developed in collaboration with NATSEM 
(University of Canberra), the School of Public Health (University of Sydney), and 
the School of Population Health (University of Queensland), and is funded by an 
ARC linkage grant with Pfizer Australia as an industry partner.
Capturing the personal and government economic impacts of health across 
society is increasingly part of clinical trials. An example is the LIFT trial, which is 
determining whether adding bovine lactoferrin to food reduces mortality and 
morbidity in infants with very low birthweight. The CTC’s health economics 
group is assessing whether the intervention is cost-effective, including the 
capacity of mothers to return to the labour force if the child does not suffer  
a serious disability, and the impact on family income. 
In 2012, the collaboration won an NHMRC Partnership Project Grant in 
collaboration with Carers Australia and Pfizer Australia as partner organisations to 
model the current and future economic impacts of becoming a carer, and Dr Emily 
Callander received an NHMRC Early Career fellowship to develop Australia’s first 
measure of long-term multidimensional poverty.
The work of the team continues to be published in highly regarded journals 
including Pain,93,94 the International Journal of Cardiology96,98,99 and Spine.97 
Health economists: rupendra 
shrestha, Hannah verry,  
deborah schofield and  
toby gould
Evidence for clinical practice and policy
24 
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Biostatistics research
Methodological studies
CTC biostatisticians undertake 
methodological research to improve 
the design and conduct of clinical 
trials and to underpin predictions  
of risk in clinical situations.
driLLiNG doWN  
iNto qUALity oF LiFe
Comparing trials of treatments for 
their effects on quality of life requires 
a single global measure of quality of 
life as a whole. Because many factors 
contribute to this, health-related 
quality of life is often ascertained 
by aggregating scores on various 
individual dimensions of quality of 
life, such as physical, psychological, 
social, and functional domains. The 
method is limited because it reduces 
multidimensional outcomes into 
a single intangible quality without 
systematic agreement on how they 
are weighted.
In a model addressing this problem, 
Annette Kifley and colleagues 
used multilevel latent variables 
(statistical hypothetical constructs 
not directly measured) to integrate 
and summarise health-related quality 
of life. They used data from a breast 
cancer trial in which quality of life 
was a key outcome. They presented 
their model in Statistics in Medicine, 
concluding that this approach can 
pinpoint wellbeing more precisely 
than other summary measures of 
quality of life.60
MetHodoLoGy
strAtiFied Additive poissoN 
ModeLs to predict risK
Predicting a patient’s risk of having a 
particular disease event is important 
in clinical practice. Such predictions 
depend on models of risk developed 
by biostatisticians. 
Even when risk factors have been 
identified, it is not always clear how 
individual risk factors combine. 
Models that arrive at an overall level 
of risk by multiplying individual 
risk factors are usual in predicting 
cardiovascular disease, but they 
are troubled by artefacts caused by 
interactions among risk factors. So 
additive models have also been used. 
CTC biostatisticians demonstrated a 
method (stratified additive Poisson 
models) of combining multiplicative 
and additive components to predict 
risk, using data from large trials of 
acute myocardial infarction.68 The 
method is an improvement over the 
multiplicative models and produced 
a more streamlined risk factor model 
by removing the need for interaction 
terms. The method is particularly 
relevant to predicting short-term 
mortality. 
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ctc BiostAtisticiAN 
eNJoys teAcHiNG ANd 
coNsULtiNG
‘We teach the biostatistical 
skills required in clinical 
research to busy clinicians 
and others in this field. 
Although the courses are 
delivered online, I enjoy the 
regular interaction with 
students and being able  
to make a difference to  
their learning. 
‘In my current consulting role 
at the Kids Research Institute 
of the Children’s Hospital 
Westmead, I provide advice 
and assistance to staff and 
students working in a range 
of areas from basic laboratory 
science to multicentre clinical 
trials. I help the researchers 
with many aspects of their 
studies, from design and data 
collection to analysis and 
interpretation of the data. 
I also help with presenting 
their results. My consulting 
experiences have been a very 
rewarding part of my career  
at the CTC.’
— liz Barnes,  
research fellow in biostatistics
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Biostatistics  
and clinical trials
Responsibility for the design and data 
analysis of the CTC’s trials lies with  
the biostatisticians. 
CTC statisticians also collaborate with 
many Australian academic groups. 
Their work covers a wide area of 
health research, as illustrated by  
the examples described here.
the international LAce trial, led 
by the University of queensland, 
compared the newer laparascopic 
approach and standard open 
abdominal surgery for endometrial 
cancer.80 The CTC contributed to the 
trial through design and analysis of 
results, which showed that patients 
having laparascopic surgery had a 
much lower rate of adverse events 
after the surgery. If further follow-up 
and analysis confirm that survival 
is equivalent, the newer surgical 
approach should become the 
standard treatment. In the meantime, 
analyses of LACE data continue, 
answering clinical questions  
about risk and prediction in 
endometrial cancer.63,79
Preeclampsia is a dangerous 
condition of pregnancy, thought to 
be related to an immune response in 
the mother. An analysis undertaken 
with clinicians from Nepean Hospital 
resulted in the novel proposal that 
the fetal adaptive immune system 
may be actively involved in initiating 
preeclampsia.32,162 The medical school 
at Nepean Hospital has also used 
biostatistical expertise in its studies 
on pelvic organ collapse, particularly 
after childbirth; the evidence arising  
is guiding surgical repair and 
prevention strategies.25,26,27
the Head and Neck cancer service 
at Westmead Hospital has published 
studies demonstrating the value  
of adjuvant radiotherapy for 
squamous cell carcinoma of the  
head and neck.77,125,126
In work with several Sydney hospitals 
funded by the dust diseases Board, 
researchers investigated factors 
predicting survival of patients with 
malignant pleural mesothelioma. 
They identified several factors, but 
especially neutrophil-to-lymphocyte 
ratio, a marker of inflammation, 
which they recommended being 
routinely used to stratify patients  
Biostatistics group at the CtC: andrew Martin, anne-sophie veilland, rachel o‘Connell, Chee lee, david espinoza, liz Barnes,  
Mark donoghoe, adrienne Kirby, Malcolm Hudson, lucy davies, alan Coates and Jodie gonzales Jennings.
for risk level in clinical trials.52 Health-
related quality of life was also related 
to inflammation and survival.53
A study by emergency physicians 
at royal prince Alfred Hospital 
showed that introducing bias into the 
clinical history significantly affects the 
subsequent interpretation of ECGs.21 
In another study, they analysed the 
relationship between injury severity 
and resource utilisation and the 
relative effect of age on these costs.28 
The results, that costs increased with 
injury severity and that falls caused 
the most expensive injuries, are 
valuable evidence for health  
policy planners.
In a complex analysis with 
implications for health planning, 
Val Gebski and his colleagues from 
the centres for disease control and 
prevention in Atlanta investigated 
the effectiveness of control 
measures for methicillin-resistant 
Staphylococcus aureus infection 
(whose consequences are slow to 
take effect) in hospital where the 
interventions were implemented at 
different times.36 They developed a 
novel step-wedge statistical model 
describing infection transmission.
Methodology
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‘Through this course I have 
developed an understanding of 
clinical research that has enabled 
me to work more effectively 
alongside our researchers, engage 
the institute’s operations in the 
research process and therefore 
contribute far more effectively to 
our research effort.’
—  Kellie ridges, operations manager at a 
medical research institute, is a student in the 
Master of Clinical trials (research) course
Master of clinical trials (research):  
a postgraduate course
Clinicians and health professionals are expected to have a thorough 
understanding of clinical trials and their regulations when conducting research 
and collaborating in Australia or internationally.
The online clinical trials research course offers formal qualifications in the 
design, conduct and interpretation of clinical trials. It was developed and is 
taught by the CTC and provides a qualification from Sydney Medical School  
at the University of Sydney.
Students—doctors, health care professionals, academics, and others working 
in clinical research— learn about research methods, clinical trials literature and 
the clinical trials process, including design, protocol development, doses of 
treatment, statistics and ethics.
edUcAtioN
‘I am an ophthalmic 
clinician-scientist and did 
the BCA course one subject 
per semester over 6 years. 
Each one added to a powerful 
statistical toolkit that 
has given me confidence 
to handle the design and 
analysis aspects of all my 
research endeavors. 
‘Becoming a trained 
statistician has improved the 
quality of my research and 
provided an unfair advantage 
when writing manuscripts 
and grant proposals.’
— robert Casson
adrienne Kirby (left),  
senior lecturer, coordinates 
the postgraduate course in  
clinical trials research
BiostAtistics coLLABorAtioN oF AUstrALiA—
AdMiNistered FroM tHe ctc
the Biostatistics collaboration of Australia (BcA) is a 
consortium of biostatistical experts from around Australia 
with representatives from universities, government and 
the pharmaceutical industry who have combined to offer a 
national (and international) program of postgraduate courses 
via an alliance of universities. the BcA program is delivered 
entirely by distance by consortium universities. since the first 
graduating year, 2003, the BcA has had 278 graduations. in 
2012, 275 students were enrolled in BcA courses.
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The CTC works with organisations around the world in collaborations that lead to better health outcomes in Australia and 
internationally. New collaborations are continually sought and then consolidated in research projects benefiting the health 
of Australians and others. 
grouP nature oF grouP CtC aCtivity
Australasian Gastro-Intestinal Trials Group 
(AGITG)
Collaborative group for gastrointestinal cancer trials: Australia, New Zealand
International collaborations: Cancer Clinical Trials Unit Scotland (CACTUS), 
Eastern Cooperative Oncology Group (ECOG), European Organisation for 
Research and Treatment of Cancer (EORTC) , European Study Group for 
Pancreatic Cancer (ESPAC) , Groupe Coopérateur Multidisciplinarie en Oncologie 
(GERCOR), National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) , 
National Surgical Adjuvant Breast and Bowel Project (NSABP), Medical Research 
Council (MRC), Oxford Clinical Trials Office, Oxford University (OCTO) , Pan-
European Trials in Alimentary Tract Cancer (PETACC)
Coordinating centre  
and collaborator
Australasian Lung Cancer Trials Group 
(ALTG)
Collaborative group for lung cancer trials: Australia, New Zealand
International collaborations: NVALT (Netherlands), NCIC CTG (Canada)
Coordinating centre  
and collaborator
Australasian Society of Thrombosis and 
Haemostasis
Professional group undertaking thrombosis trials: Australia, New Zealand Coordinating centre  
and collaborator
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG)
Collaborative group for gynaecological cancer trials: Australia, New Zealand
International collaborations: Dutch Gynaecologic Oncology Group (DGOC), 
Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), 
Gynecological Cancer Intergroup (GCIG), International Gynaecological Cancer 
Intergroup (IGCI), Gynecologic Oncology Group (GOG), Medical Research Council 
(MRC), Scottish Gynaecologic Cancer Trials Group (SGCTG)
Coordinating centre  
and collaborator
Australian and New Zealand Urogenital and 
Prostate Clinical Trials Group (ANZUP)
Collaborative group for cancer of the genitourinary system: Australia, New 
Zealand. International collaborations: Cancer Research UK (CRUK), European 
Organisation for Research and Treatment of Cancer (EORTC), Groupe 
Coopérateur Multidisciplinarie en Oncologie (GERCOR),Institute of Cancer 
Research (ICR), National Cancer Research Institute (NCRI), Swedish & Norwegian 
Testicular Cancer Project (SWENOTECA), and Wales Cancer Trials Unit (WCTU)
Coordinating centre  
and collaborator
Australian New Zealand Breast Cancer Trials 
Group (ANZ BCTG)
Collaborative group for breast cancer trials: Australia, New Zealand
International collaborations: International Breast Cancer Study Group (IBCSG), 
Breast International Group (BIG), International Breast Cancer Intervention Study 
(IBIS)
Statistical centre 
for group, including 
randomisation
Australian New Zealand Clinical Trials 
Registry (ANZCTR)
National register of clinical trials: Australia, New Zealand and international Coordinating centre
Biostatistics Collaboration of Australia Universities undertaking postgraduate education in biostatistics: Australia Coordinating centre
Cholesterol Treatment Trialists’ 
Collaboration (CTTC)
Investigators of cholesterol treatment trials: Australia, New Zealand, United 
Kingdom, United States, Italy
Coordination of meta-
analyses in heart disease
Clinical Trial Development Unit (CTDU) Partnership with the Centre for Biostatistics and Clinical Trials, Peter MacCallum 
Cancer Institute: Australia
Trial operation and 
statistical support for 
cancer trials
Cochrane Collaboration Breast Cancer Group Collaborative group undertaking systematic reviews of trial evidence: 
international
Editoral base
Cochrane Prospective Meta-Analysis 
Methods Group
Collaborative group undertaking systematic reviews of trial evidence: 
international
Coordinating centre
Cooperative Trials Group for Neuro-
Oncology (COGNO)
Collaborative group for brain cancer trials: Australia 
International collaboration: European Organisation for Research  
and Treatment of Cancer (EORTC)
Coordinating centre 
and collaborator
Early Prevention of Obesity in Children 
(EPOCH) collaboration
Prospective meta-analysis collaboration: international Data coordination centre
Fenofibrate and Event-Lowering in Diabetes 
(FIELD) Study Investigators
Collaborative group for FIELD diabetes trial genetic, molecular and follow-up 
substudies: Australia, New Zealand, Finland, Germany
Coordinating centre
INSPIRE Meta-analysis: ASPIRE and WARFASA (Italy) Member
coLLABorAtioNs
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coLLABorAtioNs
grouP nature oF grouP CtC aCtivity
International Neonatal Immunotherapy 
Study (INIS) Study Group
Collaborative group for INIS trial: Australia, New Zealand, Europe, Argentina Regional coordinating 
centre
Long-term Intervention with Pravastatin in 
Ischaemic Disease (LIPID) Study Group
Collaborative group for LIPID cholesterol-lowering trial genetic, molecular and 
follow-up substudies: Australia, New Zealand, Germany
Coordinating centre
Medical Services Advisory Committee 
(MSAC) and Department of Health and 
Ageing
Government: Australia Assessments of new 
technologies and other 
research services
Menzies Research Institute and Charles 
Darwin University
Research institution: Australia Collaborator 
Meta-analysis collaboration (AMICABLE) Meta-analysis collaboration: international Collaborator
Meta-Analysis of Preterm Patients 
on Inhaled Nitric Oxide (MAPPiNO ) 
collaboration
Meta-analysis collaboration: international Data coordination centre
Heart Foundation Nongovernment organisation: Australia Cardiovascular research
National Perinatal Epidemiology Unit 
(NPEU), University of Oxford
Research institution: UK Collaborator on the INIS 
neonatal trial
Neonatal Oxygenation Prospective Meta-
analysis (NeOProM) collaboration
Prospective meta-analysis collaboration; international Coordinating centre
NSW Cancer Council Cancer Epidemiology Research Unit Collaborator
Perinatal Antiplatelet Review of 
International Studies (PARIS) collaboration
Meta-analysis collaboration:international Co-coordinating centre
Prenatal repeat corticosteroid international 
individual-patient-data study group: 
assessing the effects using the best level of 
evidence (PRECISE) collaboration
Meta-analysis collaboration: international Collaborator
Prevention of Ventilator Induced Lung Injury 
collaborative study group (PreVILIG) 
Meta-analysis collaboration: international Data coordination centre
Primary Care Cancer Trials Group (PC4) Collaborative group: Australia Collaborator
Primary Coronary Angioplasty versus 
Thrombolysis (PCAT)
Meta-analysis collaboration: international Co-coordinating centre
Prospective Pravastatin Pooling (PPP) 
project 
Collaborative group: international Coordinating centre
RNA-based Analysis for Prediction of Islet 
Death (RAPID)
Collaborative group: Australia Collaborator
REMOVAL Collaborative group for type 1 diabetes trial: international Co-coordinating centre 
and collaborator
Royal Australasian College of Surgeons 
(RACS)
Professional society undertaking trials of surgery: Australia and New Zealand Coordinating the SNAC 
trials in breast cancer 
with the RACS
Sydney Catalyst Consortium for translational research in cancer Collaborator
T4DM Collaborative group for diabetes prevention trial: Australia Co-coordinating centre 
and collaborator
Star Child Health Meta-analysis collaboration: international Member
VIGOUR group Collaborative group for trials of heart disease: 40 countries VIGOUR leader
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trial PartiCiPants target aCCrual
neonatal disorders
current trials
APTS: Australian placental transfusion study 
ctc trial
Neonates born before 30 weeks’ gestation  1600 300
trials in follow-up
BOOST II: Benefits of oxygen saturation targeting
ctc trial
Neonates born before 28 weeks’ gestation  1200 1135
CardiovasCular disorders
trials in start-up
REMOVAL: Effects of metformin added to insulin on 
atheroma progression 
University of Glasgow and NHs-led, and ctc trial
Adults with type 1 diabetes at risk of cardiovascular 
disease
90 (ANZ):  
500 (international)
T4DM: efficacy of adding testosterone to a lifestyle 
program to prevent progression to type 2 diabetes
ctc study
Men with prediabetes and low testosterone 1500
trials in follow-up
FIELD: Fenofibrate intervention and event lowering in 
diabetes
Patients with type 2 diabetes 8000 9795
LIPID: Long-term intervention with pravastatin in 
ischaemic disease
Patients with a history of coronary heart disease 9000 9014
Breast CanCer (CollaBorating WitH raCs)
Current trials
SNAC 2: Sentinel node biopsy versus axillary clearance
RACS and CTC study
Women with operable breast cancer, stratified by 
factors including age and tumour size
 1012 266
trials in follow-up
SNAC 1: Sentinel node biopsy versus axillary clearance  
RACS and CTC study
Women with a single operable breast tumour 
<3 cm, stratified by factors including age and 
tumour size
1000 1088
gastrointestinal CanCer (CollaBorating WitH agitg)
trials in start-up
ICECREAM: Irinotecan Cetuximab Evaluation and 
Cetuximab Response Evaluation Among Mutants
AGitG and ctc study
Patients with Kras-WT metastatic colorectal 
carcinoma or a G13D mutation
100
IMPACT: Phase 2 trial using genomic sequencing and 
protein expression to direct first-line treatment 
Garvan, AGitG and ctc study
Patients with metastatic pancreatic cancer 90
Current trials
A La CART: Australian phase III randomised trial of 
laparoscopy-assisted resection compared with open 
resection
AGitG and ctc study
Patients with primary rectal cancer 470 163
ATTACHE: Timing of surgery and adjuvant chemotherapy 
for hepatic colorectal metastases
AGitG and ctc study
Patients with confirmed resectable liver 
metastases and no other disease
200 5
DOCTOR: Phase 2 trial of preoperative cisplatin, 
5-fluorouracil and docetaxel with or without radiotherapy 
for oesophageal cancer
AGitG and ctc study
Patients with resectable adenocarcinoma of the 
oesophagus not responsive to chemotherapy
150 48
GAP: Phase 2 study of gemcitabine and NAB-paclitaxel
AGitG and ctc study
Patients with resectable pancreas cancer 50 3
cUrreNt ctc triALs
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trial PartiCiPants target aCCrual
INTEGRATE: Phase 2 trial comparing regorafenib and 
placebo
AGitG and ctc-led international study
Patients with advanced oesophagogastric cancer 150 22
PAN1: Phase II study evaluating potential predictive 
biomarkers in treatment of locally advanced and 
metastatic pancreatic cancer 
AGitG and ctc study
Patients with confirmed metastatic pancreatic 
adenocarcinoma
80 8
SCOT: Short-course oncology therapy, a study of adjuvant 
chemotherapy in colorectal cancer
Mrc-led, AGitG and ctc study
Patients with fully resected stage III colorectal 
cancer
225 (ANZ):  
9500 (international)
163 (ANZ):  
4680 (international)
TACTIC: Phase 2 trial of panitumumab, cisplatin and 
gemcitabine 
AGitG and ctc study
Patients with biliary tract cancer 45 7
TOP GEAR: Randomised phase II–III trial of preoperative 
chemoradiotherapy versus preoperative chemotherapy for 
gastric cancer
AGitG and ctc study
Patients with resectable gastric cancer suitable for 
these treatments
120 (stage 1);  
632 (stage 2)
64
trials in follow-up
Adjuvant GIST: adjuvant imatinib mesylate versus no 
further therapy after complete surgery (AG0403, EORTC 
62024)
eortc-led, AGitG and ctc study
Patients with resected gastrointestinal stromal 
tumours (GIST) expressing KIT receptor
80 (ANZ) 81 (ANZ)
Advanced GIST: Relation between dose and clinical activity 
of imatinib mesylate (AG0102, EORTC 62005)
EORTC-led, AGITG and CTC study
Patients with unresectable or metastatic 
malignant gastrointestinal stromal tumours 
(GIST) expressing KIT receptor
80 (ANZ):  
600 (international)
116 (ANZ);  
946 (international)
ATTAX 3: Phase 2 trial of docetaxel, cisplatin and 
fluoropyrimidine with or without panitumumab for 
oesophagogastric cancer (AG0607OG)
AGitG and ctc study
Patients with metastatic or locally recurrent 
oesophagogastric cancer
100 77
CO.20: Phase III study of BMS-582664 with cetuximab 
versus placebo with cetuximab
Ncic ctG-led, AGitG and ctc study
Patients with metastatic colorectal carcinoma 
previously treated with combination 
chemotherapy
370 (ANZ);  
750 (international)
416 (ANZ);  
686 (international)
EORTC liver metastases: Oxaliplatin, 5-fluorouracil and 
leucovorin versus surgery for resectable colorectal cancer 
liver metastases (EORTC 40983)
eortc-led, AGitG and ctc study
Patients with colorectal cancer with resectable 
liver metastases
330 (international) 35 (ANZ);  
364 (international)
LAP07: Randomised multicentre phase III study of 
gemcitabine with or without chemoradiotherapy and with 
or without erlotinib 
Gercor-led, AGitG and ctc study
Patients with locally advanced adenocarcinoma of 
the pancreas
60 (ANZ);  
900 (international)
32 (ANZ);  
442 (international)
PETACC 6: Addition of capecitabine to preoperative 
oxaliplatin chemoradiotherapy and postoperative 
oxaliplatin chemotherapy for rectal cancer (AG0707R)
eortc (petAcc)-led, AGitG and ctc study
Patients with locally advanced rectal cancer 135 (ANZ);  
1090 (international)
127 (ANZ);  
1094 (international)
Quasar 2: Phase III study of capecitabine and bevacizumab 
as adjuvant treatment of colorectal cancer (AG0107CR)
octo-led, AGitG and ctc study
Patients with colon cancer treated by surgery 120 (ANZ);  
1892 (international)
219 (ANZ);  
1952 (international)
REGISTER: Multicentre phase II study of risk evaluation in 
GIST with selective therapy escalation for response
AGitG and ctc study
Patients with gastrointestinal stromal tumour not 
suitable for curative surgery
80 47
cUrreNt ctc triALs
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trial PartiCiPants target aCCrual
gynaeCologiCal CanCer (CollaBorating WitH anZgog)
Current trials
ANZGOG 1103: Phase I–II BNC105P combination study
ANZGoG study
Women with partly platinum-sensitive ovarian 
cancer in first or second relapse
up to 24 Phase I 
(international)
5 (ANZ); 
6 international
Outback: Phase III trial of addition of adjuvant 
chemotherapy to standard chemoradiation as primary 
treatment for cervical cancer
ANZGoG and ctc-led international study
Women with locally advanced cervical cancer  780 (international) 46 (ANZ);  
113 international
PARAGON: Phase II study of anastrozole in gynaecological 
cancers
Mrc, ANZGoG and ctc-led international study
Women with potentially hormone-responsive 
gynaecological cancers
 350 (international) 92 (ANZ); 
110 (international)
PORTEC 3: Chemo radiation and adjuvant chemotherapy 
compared with with pelvic radiation alone in high-risk 
endometrial carcinoma
GciG-led, ANZGoG and ctc study
Women with advanced endometrial carcinoma  120 (ANZ);  
670 (international)
89 (ANZ);  
499 (international)
Symptom benefit: does palliative chemotherapy improve 
symptoms in women with recurrent ovarian cancer? 
(ANZGOG 1103)
ANZGoG and pocoG study
Women with platinum-resistant or refractory 
ovarian cancer
800 (international) x185 (ANZ); 
317 (international)
trials in follow-up
ICON 6: Safety and efficacy of cediranib in combination 
with standard chemotherapy
Mrc-led, ANZGoG and ctc study
Women with with platinum-sensitive relapsed 
ovarian cancer
400 (international) 17 (ANZ);  
486 (international)
ICON 7: Randomised trial of adding bevacizumab to 
standard chemotherapy
MRC-led, ANZGOG and CTC
Women with epithelial ovarian cancer who had 
not received systemic antitumour therapy
1444 (international) 76 (ANZ); 
1450 (international)
OVAR 16: Pazopanib versus placebo for ovarian cancer 
GciG-led, ANZGoG and ctc study
Women without disease progression after 
chemotherapy for epithelial ovarian, fallopian 
tube, or primary peritoneal cancer
900 (international) 65 (ANZ);  
940 (international)
SCOTROC 4: Multicentre trial of carboplatin flat dosing vs 
intrapatient dose escalation in first-line chemotherapy
sGctG-led, ANZGoG and ctc
Women with ovarian, fallopian tube or peritoneal 
carcinoma who are unsuitable for platinum–
taxane therapy
1300 (international) 64 (ANZ);  
937 (international)
CALyPSO : phase III study comparing pegylated liposomal 
doxorubicin and carboplatin vs paclitaxel and carboplatin
GiNeco-led, ANZGoG and ctc
Women with platinum sensitive relapsed ovarian 
cancer
974 (international) 71 (ANZ): 
976 (international)
Tarceva : phase III study of erlotinib versus observation
(EORTC 55041)
eortc-led, ANZGoG and ctc
Women without disease progression after 
chemotherapy for epithelial ovarian, fallopian 
tube, or primary peritoneal cancer
830 (international) 41 (ANZ),  
830 (international)
Phase III randomised trial of paclitaxel + carboplatin versus 
triplet or sequential doublet combinations (GOG 182)
GoG-led, ANZGoG and ctc
Women with advanced stage (FIGO III-IV) 
epithelial ovarian or primary peritoneal carcinoma
4200 (international) 184 (ANZ) 
4312 (international)
Prospective study of risk-reducing salpingo-oophorectomy 
and longitudinal CA-125 screening (GOG 199)
GoG-led, ANZGoG and ctc
Women at high risk of ovarian cancer 800 (international) 83 (ANZ);
800 (international)
TRIPOD: phase II trial of intraperitoneal chemotherapy 
(ANGOG-0601)
ANGoG- and ctc-led
Women with optimally debulked stage III cancer of 
the ovary, peritoneum and fallopian tube
35-100 39
genitourinary CanCer (CollaBorating WitH anZuP)
trials in start-up
Mitomycin C added to BCG as adjuvant intravesical therapy 
for bladder cancer
ANZUp and ctc study
Patients with non-muscle-invasive bladder cancer 500
Phase 3 trial of accelerated versus standard BEP 
chemotherapy of germ cell tumours
ANZUp and ctc study
Patients with metastatic germ-cell tumours with 
intermediate or poor prognosis
500
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Current CTC trials
trial PartiCiPants target aCCrual
Current trials
SORCE: Adjuvant sorafenib for renal cell carcinoma (RE 05)
Mrc-led, ANZUp and ctc study
Patients with resected renal cell carcinoma at 
intermediate or high risk of relapse
 250 (ANZ);  
1656 (international)
2250 (ANZ);  
159 (international)
trials in follow-up
Accelerated BEP: feasibility study of accelerated BEP as 
first-line chemotherapy for advanced germ cell tumours 
(ANZGCTG 0206, ANZGOG 0603)
ANZUp, ANZGoG and ctc study
Patients with intermediate and poor-risk advanced 
germ-cell tumours (and selected good-risk 
tumours)
 25 45
Chemo & cognition: Cognitive function and treatment for 
testicular cancer (ANZGCTG 0106)
ANZUp and ctc study
Patients being treated and followed up for 
testicular cancer
154 151 
Eversun: Phase II trial of everolimus alternating with 
sunitinib for renal cell carcinoma (ANZUP 0901)
ANZUp and ctc study
Patients starting first-line systemic therapy for 
advanced renal cell carcinoma
55 56 
lung CanCer (CollaBorating WitH altg)
Current trials
BR.26: Phase III trial of PF-804 in patients with incurable, 
non-small-cell lung cancer (ALTG 09/002)
Ncic-led, ALtG and ctc study
Patients with stage IIIB or IV non-small-cell lung 
cancer
180 78
NITRO: phase III multicentre trial of adding nitroglycerine 
to first-line chemotherapy for advanced non-small-cell 
lung cancer (ALTG 06/003)
ALtG and ctc study
Patients with advanced non-small-cell lung cancer  500 250
PACT in NSCLC: Preferences for adjuvant chemotherapy in 
non-small-cell lung cancer
ALtG and ctc observational study
Patients, surgeons and oncologists 200 122 
trials in follow-up
B2P2M2: phase II trial of BNC105P as second-line 
chemotherapy for pleural mesothelioma (ALTG 09/004)
ALtG and ctc study
Patients with pleural mesothelioma which has 
progressed after pemetrexed and platinum 
chemotherapy
 30 30
Brain tuMours (CollaBorating WitH Cogno)
trials in start-up
Phase II study of acetazolamide plus dexamethasone 
versus dexamethasone for cerebral oedema in high-grade 
glioma
coGNo and ctc study
Patients with high-grade glioma requiring 
new dexamethasone or dose increase due to 
progressive or recurrent disease
 86
Phase II study of psycho-educational intervention in 
patients with primary brain tumour
pocoG-led and coGNo study
Patients with confirmed primary brain tumours  60
Current trials
CABARET: Phase II study of carboplatin and bevacizumab 
in recurrent glioblastoma multiforme
coGNo and ctc study
Patients aged 18 years and over with recurrent 
grade IV glioma after radiotherapy and 
temozolomide chemotherapy
122 (part 1); 
60 (part 2)
122 (part 1);
47 (part 2)
CATNON: Phase III trial of concurrent and adjuvant 
temozolomide chemotherapy for anaplastic glioma 
(EORTC 26053-22054)
eortc-led coGNo and ctc study
Patients with non-1p/19q- deleted anaplastic 
glioma
 100 (ANZ);  
748 (international)
43 (ANZ); 
419 (international)
SEED: Self-reported evaluation of the adverse effects of 
dexamethasone
coGNo and ctc study
Patients with brain tumours or brain metastases or 
advanced cancer using steroids
50 patients,  
50 caregivers
12
trials in follow-up
LGG: Phase III study of primary chemotherapy with 
temozolomide versus radiotherapy (TROG 06.01, EORTC 
22033-26033)
eortc, coGNo, troG and ctc study
Patients with low-grade glioma, stratified for 
genetic 1p loss
100 (ANZ);  
560 (international)
79 (ANZ);  
419 (international)
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AStat, senior lecturer
research fellows
Elizabeth E Barnes, BAppSc, MStat
Christopher SB Brown, BSc
Diana Zannino, BSc(hons), MSc
Biostatisticians
Mark D Chatfield, BA, MSc
Mark W Donoghoe, BSc(hons)
David Espinoza, BSc(hons)
Marion Fournier, MSc
Kristy P Mann, BScAgr(hons)
Rachel L O’Connell, BMath, MMedStat, PhD
Anne-Sophie Veillard, BSc, MSc
BiostAtistics coLLABorAtioN oF 
AUstrALiA (BcA)
Erica Jobling, executive officer
Helen Johnson, BA, MMuseumStud
iNForMAtioN systeMs
infrastructure
Dinh Tran, BMath, MCompSc, infrastructure 
manager
Asanka Perera, BSc, computer systems officer
Thuyen Vu, BSc, computer systems officer
database administration
Anh Tai Nguyen, BMath, database 
administrator
software development
Colin Sutton, BSc, MSc, IT systems 
development manager
Seshu Atluri, BE, software engineer
BUsiNess AdMiNistrAtioN
Kim Russell-Cooper, BA(hons), MBA, general 
manager
Mira Mikulic, receptionist
Lia Sherwood, BBiomedSc, MSc, grants and 
contracts coordinator
Finance
Paul Smyth, BCom, CPA, finance manager
Agnes Ho, MPracAcc, CPA, finance officer
Maki Joseph, DipEd, finance officer
Carlos Sterling, BEng, MBA, finance officer
Human resources
Cynthia Carr, BEd(HRD), human resources and 
administration manager
Suzanne Everett, BSW, human resources and 
administration coordinator
pUBLicAtioNs
Rhana Pike, BA, MA, GradCert, ELS, CMPP, 
senior publications officer
reseArcH stUdeNts
Prunella Blinman, BMed, FRACP
Jordan Fulcher, BSc(Med), MB BS,
Deme Karikios, BSc, MB BS, FRACP
Annette Kifley, MB BS, MAppStat
Zhixin Liu, PhD
Kushwin Rajamani, MB BCh
Michaella Smith, BSc, MB BS(hons), MMSc
Ru-Dee Ting, MB BS, FRACP
AcAdeMic stAFF
Lisa M Askie, BN, MPH, PhD, senior research 
fellow
Elizabeth E Barnes, BAppSc, MStat, research 
fellow
Christopher SB Brown, BSc, research fellow
Karen Byth, BSc(hons), MSc, PhD, DIC, CStat 
RSS, senior lecturer
Emily J Callander, BA, research officer
Hannah Carter (Verry), BEc, research associate
Val J Gebski, BA, MStat, principal research 
fellow and professor
Toby Gould, BA, BSc, MPH, associate lecturer
Wendy Hague, MB BS, MBA, PhD, senior 
research fellow
Anandwardhan A Hardikar, BSc, MSc, PhD,  
associate professor
Andrzej S Januszewski, MD, PhD, senior 
research fellow
Alicia J Jenkins, MB BS, MD, MRCP, FRACP, 
FRCP, professor
Anthony C Keech, MB BS, MSc, FRACP, 
principal research fellow and professor
Adrienne C Kirby, BSc(hons), MSc, senior 
lecturer
Chee K Lee, MB BS(hons), MMedSc, MBiostat, 
PhD, FRACP, research fellow
Sally (Sarah) J Lord, MB BS, DipPaed, MS, 
FRACGP, research fellow
Andrew J Martin, BA, MA, GradDip, PhD, 
AStat, senior lecturer
Rachel L O’Connell, BMath, MMedStat, PhD, 
research fellow
Deborah J Schofield, BSpPath, GradDipComp, 
PhD, professor
Rupendra N Shrestha, MSc, PhD, research 
fellow
R John Simes, BSc(Med)(hons), MB BS(hons), 
MD, SM, FRACP, senior principal research 
fellow and professor
Katrin M Sjoquist, BSc(Med), MB BS, FRACP, 
clinical research fellow
Martin R Stockler, MB BS(hons), MSc, FRACP, 
associate professor
Sonia yip, BSc(hons), PhD, senior  
research fellow
Report-TEXT29-08-13.indd   35 29/08/2013   11:49:24 PM
36 NHMRC CLINICAL TRIALS CENTRE: 2012 RESEARCH REPORT
Honorary associates of the ctc
Associate Professor Meera R Agar, COGNO 
scientific advisory committee
Dr Andrew Barbour, PI, DOCTOR and GAP 
trials (AGITG)
Dr Sally Baron-Hay, ANZGOG executive
Dr David Bernshaw, ANZGOG executive
Dr Andrew Berry, BOOST II safety and data 
monitoring committee chair
Dr Andrew Biankin, PI, LAP07 trial (AGITG)
Dr Alex Boussioutas, Gastric trial (AGITG)
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sally Lord
Jillian Patterson: MBiostat
Andrew Martin
Claudia Dobler, PhD
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Emily Callander: PhD
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Deme Karikios: PhD
rupendra shrestha
Emily Callander: PhD
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Martin stockler
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exterNAL coMMittees
John simes
Australia & New Zealand Breast Cancer 
Trials Group (ANZBCTG) scientific advisory 
committee
Aspirin to Prevent Recurrent Venous 
Thrombo-embolism (ASPIRE) trial 
management committee (chair)
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee, 
operations executive committee, MAX trial 
management committee
Australian New Zealand Clinical Trials 
Registry (ANZCTR) policy advisory 
committee
Cholesterol Treatment Trialists Collaboration 
(CTTC) (joint coordinator)
Cooperative Trials Group for Neuro-
Oncology (COGNO) scientific advisory 
committee (deputy chair), management 
committee, operations executive
Benefits of Oxygen Saturation Targeting 
(BOOST) II trial management committee
Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) management 
committee, executive, and cost-
effectiveness subcommittee
Intensive Blood Pressure Reduction 
for Acute Cerebral Haemorrhage Trial 
(INTERACT) safety and data monitoring 
committee (chair)
International Breast Cancer Intervention 
Study (IBIS-II) international steering 
committee
International Trials of Aspirin to Prevent 
Recurrent Venous Thrombo-embolism 
(INSPIRE) steering committee
International Trials of Aspirin to Prevent 
Recurrent Venous Thrombo-Embolism 
(INSPIRE) steering committee (chair)
Kanyini GAP Polypill Study safety and data 
monitoring committee (chair)
Long-term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee, executive, and biomarker 
subcommittee
National Health and Medical Research 
Council Academy
NHMRC Clinical Trials Centre management 
review committee and scientific advisory 
committee
Sentinel Biopsy versus Axillary Clearance 
(SNAC) trial management committee
Sydney Catalyst governing council and 
scientific advisory committee
Trials associate editor
Virtual Coordinating Centre for International 
Collaborative Cardiovascular Research 
(VIGOUR) statistical group (chair) and a 
VIGOUR leader
Anthony Keech
Cholesterol Treatment Trialists’ 
Collaboration (CTTC) (joint coordinator and 
convenor)
FAME-1 diabetes trial steering committee 
(chair)
Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) management 
committee (principal investigator and study 
chairman), and quality-of-life and cost-
effectiveness, ophthalmology, and scientific 
substudies committees
Long-term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) study 
management committee and executive
NHMRC Clinical Trials Centre management 
review committee and scientific advisory 
committee
National Health and Medical Research 
Council grant review panel
PLoS Medicine editorial board
REMOVAL trial steering committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
Lisa Askie
Antenatal Magnesium IPD International 
Collaboration (AMICABLE) individual 
patient data collaboration steering 
committee
Cochrane Collaboration prospective 
meta-analysis methods working group (co-
convenor) and methods editorial board
Early Prevention of Childhood Obesity 
(EPOCH) prospective meta-analysis 
collaboration steering committee (chair)
International Clinical Trials Registry 
Platform, World Health Organization, best 
practice group
International Forum for Standards for 
Research in Children sample size and 
data safety monitoring committee 
subcommittee
Meta-Analysis of Preterm Patients 
on Inhaled Nitric Oxide (MAPPINO) 
Collaboration steering group
Neonatal Oxygen Prospective Meta-
analysis (NeOProM) collaboration steering 
committee (chair)
NHMRC Project Grant Review Panel for 
Clinical Trials
Perinatal Antiplatelet Review of 
International Studies (PARIS) collaboration 
steering committee (chair)
PLoS ONE academic editor
Prenatal Repeat Corticosteroid International 
IPD Study Group: Assessing the Effects 
Using the Best Level of Evidence (PRECISE) 
steering committee
Prevention of Ventilation Induced Lung 
Injury Collaborative Group (PREVILIG) 
steering committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
Systematic Reviews editorial board
elizabeth Barnes
Outback trial management committee 
(ANZGOG)
DOCTOR trial management committee 
(AGITG)
Amy Boland
Australasian Gastro-Intestinal Trials Group 
(AGITG) trials operations committee, upper 
and lower working parties
INTEGRATE trial operations executive
christopher Brown
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee, 
operational executive committee; NITRO 
trial management committee, B2P2M2 trial 
management committee
Cooperative Trials Group for Neuro-
Oncology (COGNO) scientific advisory 
committee, operational executive 
committee; CABARET trial management 
committee; SEED trial study management 
committee
Jenny chow
Cancer Institute NSW Neuro-oncology 
Group (NSWOG), COGNO operations 
executive, management committee, annual 
scientific meeting organising committee, 
COSA executive officers network and 
associated working groups
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xanthi coskinas
Australasian Lung cancer Trials Group 
(ALTG) scientific advisory committee, 
operational executive committee; NITRO 
trial management committee, B2P2M2 trial 
management committee, PACT in NSCLC 
trial management committee
trevor France
Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group (ANZUP) 
operations executive committee, scientific 
advisory committee, and Accelerated BEP, 
Aprepitant and EVERSUN trial management 
committees
Co-operative Trials Group for Neuro-
Oncology (COGNO) operations executive 
and scientific advisory committees, and 
CABARET and CATNON trial management 
committees
val Gebski
AGITG scientific advisory committee and 
MAX, TOPGEAR, IMPACT, PAN-1, ATTACHE, 
ATTAX3, TACTIC, DOCTOR, ICECREAM and 
REGISTER trial management committees
ANZ BCTG scientific advisory committee
ANZGOG Research Advisory Committee and 
PARAGON and OUTBACK trial management 
committees
ANZUP scientific advisory committee 
and Accelerated BEP and EVERSUN trial 
management committees
Australasian Kidney Trials Network advisory 
board
Biostatistics Collaboration of Australia 
steering and teaching committees
Crown Princess Mary Cancer Care Centre 
(Westmead) Radiation Oncology research 
committee
GCIG/GINECO GCIG intergroup study 
comparing pegylated liposomal doxorubicin 
(Caelyx) and carboplatin versus paclitaxel 
and carboplatin in patients with epithelial 
ovarian cancer trial management committee
Group statistician: Australia & New Zealand 
Breast Cancer Trials Group (ANZBCTG); 
Australasian Gastro-Instestinal Trials 
Group (AGITG); Australian New Zealand 
Gynaecological Oncology Group (ANZGOG); 
Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group (ANZUP); 
Trans-Tasman Radiation Oncology Group 
(TROG)
Independent safety and data monitoring 
committees: Bevacizumab use in platinum-
resistant epithelial ovarian cancer; CLASSIC 
(Adjuvant Chemotherapy versus Surgery 
in Gastric Adenocarcinoma); GAS (Effect 
of Spinal versus General Anaesthesia in 
Neonates undergoing Hernia Repair); 
TO2RPIDO (Targeted Oxygenation in the 
Resuscitation of Premature Infants and their 
Developmental Outcome)
LACC (Laparoscopic Surgery versus 
Hysterectomy in Patients with Cervical 
Cancer) trial management committee 
LACE (Laparoscopic Surgery versus 
Hysterectomy in Patients with Endometrial 
Cancer) trial management committee
LATER, NeoGem, GALA and SORBET trial 
management committees
NSW Health Central Sydney Area ethics 
committee clinical trials subcommittee
SNAC trial management committee
T4DM trial management committee
Alpana Ghadge
Benefits of Oxygen Saturation Targeting 
(BOOST) II trial management committee
Westmead international update 
management committee
Wendy Hague
Aspirin to Prevent Recurrent Venous 
Thromboembolism (ASPIRE) management 
committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) trials operations committee
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) trials 
operations committee
A La CaRT trial management committee
Australian Placental Transfusion Study 
(APTS) management committee
Benefits of Oxygen Saturation Targeting 
(BOOST II) management committee
Cancer Australia Clinical Trials Development 
Unit (CTDU) program management 
committee and strategic advisory 
committee
Cancer Institute NSW human research ethics 
committee
Cancer Institute NSW infrastructure grant 
subcommittee
International Neonatal Immunotherapy 
Study (INIS) Australian and New Zealand 
management committee
International Trials of Aspirin to Prevent 
Recurrent Venous Thrombo-Embolism 
(INSPIRE) steering committee
Long-Term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee
Sentinel Biopsy versus Axillary Clearance 
(SNAC) 1 and SNAC 2 trial management 
committees
Anandwardhan Hardikar
Islet Society, Stockholm, Sweden, vice-
president
Islets editorial board
Lifestyle Interactions in Fenofibrate and the 
Epigenome (FIELD-LIFE), co-investigator
MicroRNAs in Diabetes and Obesity, editor-
in-chief
NHMRC Grant Review Panel member for 
Diabetes/ Obesity/ Stem cell panels
NHMRC Translational Research Faculty 
member
Review of Diabetic Studies, editorial and 
review board
RNA-based Analysis for Prediction of Islet 
Death (RAPID), principal investigator
Special issue on non-coding RNAs, 
Experimental Diabetes Research, chief guest 
editor
Stem Cells and Discovery, editor
World Journal of Diabetes, editorial board
Alicia Jenkins
Australian Diabetes Society council member 
and treasurer
Insulin For Life Australia and Global and 
Insulin For Life USA board member
International Diabeted Federation Life For a 
Child program board member
REMOVAL study of metformin in type 1 
diabetes, co-principal investigator and 
Australian lead
TEAMSNET telehealth initiative principal 
investigator
Adrienne Kirby
Combination Antibiotic Treatment for 
Methicillin Resistant Staphylococcus Aureus 
(CAMERA) trial management committee
Faculty of Medicine, University of Sydney 
postgraduate coursework committee
International Trials of Aspirin to Prevent 
Recurrent Venous Thrombo-Embolism 
(INSPIRE) steering committee
Long-Term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) management 
committee
Randomised Trial on Surgical Treatment for 
Otitis Media in children Living in Remote 
Australian Communities trial management 
committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
Ann Livingstone
Co-operative Trials Group for Neuro-
Oncology (COGNO) operations executive 
and scientific advisory committees, 
and CABARET, CATNON and SEED trial 
management committees
sally Lord
Protocol Advisory Committee (PASC) for 
Medical Services Advisory Committee
European Federation of Clinical Chemistry 
and Laboratory Medicine Test Evaluation 
Working Group
McMaster University Evidence-based 
Practice Center assessment of the Use of 
Natriuretic Peptide Measurement in the 
Management of Heart Failure
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Andrew Martin
Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group (ANZUP) 
scientific advisory committee
BLOCADE safety data monitoring 
committee
ONTRAC, ProCare, INTEGRATE, EPOCH, 
NeuHorizons, LIFT and EVERSUN trial 
management committees 
Julie Martyn
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee, operations executive 
committee and study coordinators 
committee
Gynecological Cancer Intergroup (GCIG) 
harmonisation and statistics committee 
(chair)
ICON-6, ICON-7, PORTEC-3 and OVAR-16 
international steering committees
TRIPOD, Symptom Benefit, PORTEC-3 and 
Outback trial management committees
danielle Miller
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive committee 
and TOPGEAR trial management committee
Primary Care Collaborative Cancer Clinical 
Trials Group (PC4) operations team and 
scientific advisory committee 
Sydney Catalyst operations committee and 
executive committee
rebecca Mister
Aspirin to Prevent Recurrent Venous 
Thromboembolism (ASPIRE) management 
committee
International Trials of Aspirin to Prevent 
Recurrent Venous Thrombo-Embolism 
(INSPIRE) steering committee
Rachel O’Connell
PARAGON and Symptom Benefit trial 
management committees (ANZGOG)
PAN-1 and TOPGEAR trial management 
committees (AGITG)
rhana pike
Australasian Medical Writers Association 
executive committee
deborah schofield
Australian Government Department of 
Health and Ageing Professional Programs 
and Services Advisory Committee (PPSAC) 
research and development committee,
Department of Health North Coast Area 
Health Service workforce development plan 
implementation steering committee
Health Workforce Australia expert reference 
group
University of Sydney School of Public Health 
research committee
University of Sydney vice-chancellor’s health 
strategy group for intergovernmental 
relations
Lucille sebastian
International Neonatal Immunotherapy 
Study (INIS) Australian and New Zealand 
management committee
Australian Placental Transfusion Study 
(APTS) management committee
Australian Placental Transfusion Study 
echocardiography substudy management 
committee
Katrin sjoquist
Australia Asia-Pacific Clinical Oncology 
Research Development (ACORD) workshop 
steering committee, alumni committee 
(chair), future faculty fellow
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee and opera tions 
executive committee, Symptom Benefit trial 
management committee, PARAGON trial 
management committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee and 
operations executive committee, PAN1 trial 
management committee (CTC clinical lead), 
INTEGRATE trial management committee 
(CTC clinical lead) and international trial 
management group, ATTACHE, ATTAX3 and 
TACTIC trial management committees
Martin stockler
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee and 
operations executive
Australia Asia-Pacific Clinical Oncology 
Research Development (ACORD) workshop 
steering committee (convenor)
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee
Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group (ANZUP) 
scientific advisory committee, operations 
executive and Accelerated BEP, Aprepitant, 
Chemo & Cognition and EVERSUN trial 
management committees
Cancer Council Australia national oncology 
education committee
European Union Health & Innovation grant 
review board
Journal of Clinical Oncology editorial board
National Cancer Institute (NCI) Intergroup 
health related quality-of-life committee
National Health and Medical Research 
Council grant review panels for oncology
University of Sydney Faculty of Medicine 
oncology block committee (chair), EBM 
in GMP3/4 (chair), evidence-based 
medicine resource group, integrated clinical 
attachment committee and USMP cancer 
planning committee
Burcu vachan (to september)
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive
Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group (ANZUP) 
operations executive 
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) operations 
executive 
Australasian Lung Cancer Trials Group 
(ALTG) operations executive 
Cancer Institute NSW infrastructure grant 
subcommittee
Cooperative Trials Group for Neuro-
Oncology (COGNO) operations executive
Anne-sophie veillard
ATTAX3 trial management committee
Kate Wilson
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive committee, 
scientific advisory committee, study 
coordinators subcommittee (chair), annual 
scientific meeting committee, and MAX, 
Quasar 2, PETACC6, A La CaRT and SUPER 
trial management committees
Cancer Institute NSW infrastructure grant 
subcommittee
Nicole Wong
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive committee 
and ATTACHE, LAP07, SCOT, ATTAX 3, 
PAN1 and TACTIC trial management 
committees
sonia yip
Association of Regulatory and Clinical 
Scientists (ARCS Australia) Annual Scientific 
Congress organising committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive and biological 
subcommittee
Australian and New Zealand Urogenital and 
Prostate Group (ANZUP) scientific advisory 
committee, renal cell subcommittee, germ 
cell subcommittee, and EVERSUN and 
SORCE trial management committees
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee
Sydney Cancer Conference co-chair
Sydney Catalyst: Translational Cancer 
Research Centre of Central Sydney 
and Regional NSW scientific advisory 
committee, operations executive committee 
and T1 working party.
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John simes
Decision analysis, Master of Public Health 
and Master of Medicine, University of 
Sydney
Anthony Keech
Royal Prince Alfred Hospital cardiology 
training, and clinical tutor 
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney 
Master of Clinical Trials, University of Sydney 
(coordinator)
Lisa Askie
Advanced systematic reviews, Master of 
Clinical Epidemiology, University of Sydney 
(co-coordinator)
Controlled clinical trials, Master of Public 
Health, University of Sydney
Critical appraisal of evidence, Master of 
Clinical Trials, University of Sydney
Evidence-based medicine in the clinical 
years, University of Sydney Medical Program
elizabeth Barnes
Basic sciences in oncology, NSW Cancer 
Council
Principles of statistical inference, and 
teaching committee, Biostatistics 
Collaboration of Australia
Understanding trials methods, Master of 
Clinical Trials, University of Sydney
christopher Brown
Advanced clinical trials, Biostatistics 
Collaboration of Australia
Basic sciences in oncology, NSW Cancer 
Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Mark donoghoe
Basic sciences in oncology, Health Education 
and Training Institute
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
val Gebski
Advanced clinical trials, Biostatistics 
Collaboration of Australia (coordinator)
Basic sciences in oncology, NSW Cancer 
Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Radiation oncology training, RACR trainees, 
Westmead Hospital, NSW Cancer Council
Wendy Hague
Project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials Research, 
University of Sydney
Adrienne Kirby
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Trial design and methods, Master of Clinical 
Trials, University of Sydney (coordinator)
Master of Clinical Trials, University of Sydney 
(course coordinator)
chee Lee
Global biomarker studies, Master of Clinical 
Trials, University of Sydney
sally Lord
Advanced evaluation of diagnostic tests, 
and Decision analysis, Master of Public 
Health and Master of Medicine, University 
of Sydney
Biomarker studies, Master of Clinical Trials, 
University of Sydney
Critical appraisal, Basic sciences in oncology, 
NSW Cancer Council
Evidence-based medicine, University of 
Sydney Medical Program
Kristy Mann
Advanced systematic reviews, Master of 
Clinical Epidemiology, University of Sydney
Basic sciences in oncology, NSW Cancer 
Council
Critical appraisal of evidence and 
Understanding trial methods, Master of 
Clinical Trials, University of Sydney
Andrew Martin
Decision analysis (coordinator) and 
Controlled clinical trials (coordinator), 
Master of Public Health and Master of 
Medicine, University of Sydney
Interpretation of trial analyses (coordinator), 
Master of Clinical Trials, University of Sydney
rebecca Mister
Project management in clinical trials: 
development, leadership and problem 
solving, Master of fClinical Trials Research, 
University of Sydney
rachel o’connell
Principles of statistical inference, 
Biostatistics Collaboration of Australia 
(coordinator)
Advanced trial design, Master of Clinical 
Trials Research, University of Sydney
Chee lee and lukas staub, 
university of sydney Phd 
graduates with supervisor, 
Professor John simes
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deborah schofield
Health workforce policy analysis, School of Public Health, University 
of Sydney
Katrin sjoquist
Evidence-based medicine, University of Sydney Medical Program
Australia & Asia-Pacific Clinical Oncology Research Development 
(ACORD) faculty
Martin stockler
Australia & Asia-Pacific Clinical Oncology Research Development 
(ACORD) convenor, and international steering committee workshop 
(chair)
Making sense of cancer clinical trials for NSW medical oncology 
trainees (convenor)
Clinical epidemiology for physician trainees, Royal Prince Alfred 
Hospital
Evidence-based medicine in the clinical years, (chair and coordinator), 
and Oncology and palliative care (block chair), University of Sydney 
Medical Program
Medical oncology clinical training, Royal Prince Alfred Hospital
Patient-based measures, Master of Medicine, University of Sydney 
(course coordinator)
Project management in clinical trials: development, leadership and 
problem solving, Master of Clinical Trials Research, University of 
Sydney
Burcu vachan
Project management in clinical trials: development, leadership and 
problem solving, Master of Clinical Trials Research, University of 
Sydney
Anne-sophie veillard
Trial design and methods, Master of Clinical Trials, University of 
Sydney
sonia yip
Global biomarker studies, Master of Clinical Trials, University of 
Sydney
Oncology problem-based learning in the clinical years, University of 
Sydney Medical Program
ctc’s research funding
π NHMRC
π Cancer Institute NSW and Cancer Australia
π Other public funding
π Overseas research grants
π Pharmaceutical industry
π Other
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